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ABSTRACT 
This is a retrospective study conducted on Sudanese patients 
in the period January 2004 to December 2005 at Ibn Sina Hospital, 
Soba University Hospital, as well as the National Health Laboratory, 
Khartoum, Sudan. 
The study aimed to determine the histopathological pattern of 
urinary bladder neoplasms and to show the distribution of age, sex, 
original distribution, risk factors, and clinical presentations of it in 
Sudanese patients with verification of the different therapeutic options 
and the outcome. 
One hundred and six patients with urinary bladder neoplasms 
were included in the study. The commonest age group was 60-<80 
years and the age for all patients ranges between 18-90 years with a 
male to female ratio of 6.2:1. 
Urinary bladder neoplasms showed some ethno-geographic 
variations in Sudan. The majority of these cases were from the 
Northern and Western regions and a high incidence was found 
among Gaaleen tribe. Transitional cell carcinoma was found in 67.9% 
of the patients, 44% of them were high grade and 36.8% were muscle 
invading at presentation. Both WHO (1973) and the WHO/ISUP 
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(2004) grading systems were used in this study and close findings 
were obtained. This study revealed a significant relationship between 
tumour grade as well as muscle invasion and the outcome of urinary 
bladder neoplasms (P=0.006 and P=0.002, respectively).  
Squamous cell carcinoma accounts for 24.5% of the cases, 
84.6% of them had a positive history of urinary shistosomiasis. In this 
study, there was a highly significant relationship between urinary 
shistosomiasis and squamous cell carcinoma (P=0.0001). 
Nevertheless, no correlation between tobacco smoking and 
transitional cell carcinoma was found (P=0.275). These findings 
compared with those from other countries. 
In conclusion, urinary bladder neoplasms are increasing in 
number in Sudan and they share some epidemiological features with 
other developing countries and others with developed countries. Poor 
record keeping and registration may have contributed to the low 
number of patients enrolled into the study. There is a need for 
thorough prospective study to find out the actual prevalence and 
related risk factors of urinary bladder neoplasms in Sudan. We stress 
the significance of the public health education and the benefits of 
bladder cancer screening program to improve the outcome. 
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 ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ
 ﻣﻠﺨﺺ اﻻﻃﺮوﺣﺔ
 
ﺟﺮﻳﺖ ﻋﻠѧﻰ اﻟﻤﺮﺿѧﻰ اﻟѧﺴﻮداﻧﻴﻴﻦ ﻓѧﻰ اﻟﻔﺘѧﺮة  هﺬﻩ دراﺳﺔ ﻗﻬﻘﺮﻳﺔ  أ ُ      
 ﻣﻦ ﻣﺴﺘﺸﻔﻰ اﺑѧﻦ ﺳѧﻴﻨﺎ و  ﻓﻰ آﻞﱟ 5002 و ﺣﺘﻰ دﻳﺴﻤﺒﺮ 4002ﻣﻦ ﻳﻨﺎﻳﺮ 
ﻟѧѧѧﻰ اﻟﻤﻌﻤѧѧѧﻞ اﻟѧѧѧﺼﺤﻰ اﻟﻘѧѧѧﻮﻣﻰ إﺿѧѧѧﺎﻓﺔ  ﻣﺴﺘѧѧѧﺸﻔﻰ ﺳѧѧѧﻮﺑﺎ اﻟﺠѧѧѧﺎﻣﻌﻰ ﺑﺎﻹ 
  .  اﻟﺴﻮدان–ﺑﺎﻟﺨﺮﻃﻮم 
م ﻣﺮاﺿѧﻰ ﻷورا ف هﺬﻩ اﻟﺪراﺳﺔ اﻟﻰ ﺗﺤﺪﻳѧﺪ اﻟѧﻨﻤﻂ اﻟﻨѧﺴﻴﺠﻰ اﻹ  ﺗﻬُﺪ      
 ، اﻟﺠѧѧﻨﺲ ،  ﻣѧѧﻦ اﻟﻌﻤѧѧﺮاﻟﻤﺜﺎﻧѧѧﺔ اﻟﺒﻮﻟﻴѧѧﺔ اﻟﺨﺒﻴﺜѧѧﺔ وﺗﻮﺿѧѧﻴﺢ ﺗﻮزﻳѧѧﻊ آѧѧﻞﱟ 
ﻖ ﻣѧѧﻦ  واﻟﻌﻼﻣѧѧﺎت اﻟѧѧﺴﺮﻳﺮﻳﺔ وآѧѧﺬﻟﻚ اﻟﺘﺤﻘﱡѧѧ ، ﻋﻮاﻣѧѧﻞ اﻟﺨﻄѧѧﻮرة،اﻷﺻѧѧﻞ
  . اﻟﺨﻴﺎرات اﻟﻌﻼﺟﻴﺔ اﻟﻤﺨﺘﻠﻔﺔ وﺣﺼﻴﻠﺔ اﻟﻤﺮض
 09-81 ﺗﺮاوﺣﺖ أﻋﻤѧﺎرهﻢ ﻣѧﺎ ﺑѧﻴﻦ  ﻣﺮﻳﻀﺎ ً601 ﺷﻤﻠﺖ اﻟﺪراﺳﺔ        
 08 ﻣѧﻦ  وأﻗѧﻞ ّ-06آﺜѧﺮ ﺷѧﻴﻮﻋﺎ هѧﻰ وآﺎﻧﺖ اﻟﻤﺠﻤﻮﻋﺔ اﻟﻌﻤﺮﻳﺔ اﻷ ، ﻋﺎﻣًﺎ
آﺎﻧﺖ أآﺜѧﺮ اﻟﺤѧﺎﻻت ﻣѧﻦ ﺷѧﻤﺎل ﺛѧﻢ  . 1 :2.6ﻧﺎث ﻧﺴﺒﺔ اﻟﺬآﻮر ﻟﻺ . ﻋﺎﻣﺎ
  .  آﺎﻧﺖ هﻰ ﻗﺒﻴﻠﺔ اﻟﺠﻌﻠﻴﻴﻦﻏﺮب اﻟﺴﻮدان وأآﺜﺮ اﻟﻘﺒﺎﺋﻞ ﺗﺄﺛﺮًا
 هѧﻮ ﺳѧﺮﻃﺎﻧﺔ  اﻟﻨﻤﻂ اﻟﻨѧﺴﻴﺠﻰ اﻷآﺜѧﺮ ﺷѧﻴﻮﻋﺎ ً أوﺿﺤﺖ اﻟﺪراﺳﺔ أنﱠ       
 ،ﻣѧѧﻦ اﻟﻤﺮﺿѧѧﻰ  % ( 9.76) ﺟѧѧﺪت ﻓѧѧﻰ ُو( اﻟﻤﺘﺤﻮﻟѧѧﺔ )اﻟﺨﻠﻴѧѧﺔ اﻟﻌѧѧﺎﺑﺮة 
آﺎﻧѧѧѧﺖ ﻏﺎزﻳѧѧѧѧﺔ % 8.63ﻣѧѧѧﻨﻬﻢ ﻓѧѧѧﻰ ﻣﺮﺣﻠѧѧѧﺔ ﻣﺮﺿѧѧѧﻴﺔ ﻋﺎﻟﻴѧѧѧﺔ و % 44
  . ﻟﻠﻌﻀﻼت ﻋﻨﺪ ﻗﺪوﻣﻬﻢ
 وﻧﻈﺎم ﻣﻨﻈﻤﺔ ( 3791) ﻣﻦ ﻧﻈﺎم ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ       آﻞﱟ
اﻟﺠﻤﻌﻴﺔ اﻟﻌﺎﻟﻤﻴﺔ  ﻻﺧﺘﺼﺎﺻﻰ ﻋﻠﻢ أﻣﺮاض اﻟﻤﺴﺎﻟﻚ / اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ 
ﻰ هﺬﻩ اﻟﺪراﺳﺔ ﺳﺘﻌﻤﻼ ﻓ ﻟﺪراﺳﺔ ﻣﺮاﺣﻞ اﻟﻤﺮض ﻗﺪ ُا(4002 )اﻟﺒﻮﻟﻴﺔ 
  .ل ﻋﻠﻰ   ﻧﺘﺎﺋﺞ ﻣﺘﻘﺎرﺑﺔﻟﺤﺼﻮ اوﻗﺪ ﺗَﻢ
 اﻟﺪراﺳѧѧѧﺔ   أﻇﻬѧѧѧﺮت ﻋﻼﻗѧѧѧﺔ ذات ﻣﻐѧѧѧﺰى ﺑѧѧѧﻴﻦ ﻣﺮﺣﻠѧѧѧﺔ اﻟѧѧѧﻮرم ﻩ  هѧѧѧﺬ   
اﻟﻤﺮﺿѧѧѧﻴﺔ وآѧѧѧﺬﻟﻚ ﻏѧѧѧﺰوﻩ ﻟﻠﻌѧѧѧﻀﻼت وﺣѧѧѧﺼﻴﻠﺔ أورام اﻟﻤﺜﺎﻧѧѧѧﺔ اﻟﺒﻮﻟﻴѧѧѧﺔ 
  (.  ﻋﻠﻰ اﻟﺘﻮاﻟﻰP=600.0و P  =)200.0اﻟﺨﺒﻴﺜﺔ 
  .ﻣѧѧѧѧﻦ اﻟﺤѧѧѧѧﺎﻻت % 5.42ﺳѧѧѧѧﺮﻃﺎﻧﺔ اﻟﺨﻠﻴѧѧѧѧﺔ اﻟﻈﻬﺎرﻳѧѧѧѧﺔ ﺷѧѧѧѧّﻜﻠﺖ 
ﻣѧѧﻦ هѧѧﺆﻻء اﻟﻤﺮﺿѧѧﻰ ﻟﻬѧѧﻢ ﺗѧѧﺄرﻳﺦ اﻳﺠѧѧﺎﺑﻰ ﻟﻼﺻѧѧﺎﺑﺔ ﺑﺒﻠﻬﺎرﺳѧѧﻴﺎ % 6.48
X 
ﻓﻰ هѧﺬﻩ اﻟﺪراﺳѧﺔ هﻨѧﺎك ﻋﻼﻗѧﺔ ذات ﻣﻐѧﺰى ﻋѧﺎﻟﻰ ﺑѧﻴﻦ . اﻟﻤﺠﺎرى اﻟﺒﻮﻟﻴﺔ 
 P(=1000.0)ﺑﻠﻬﺎرﺳѧﻴﺎ اﻟﻤﺠѧﺎرى اﻟﺒﻮﻟﻴѧﺔ وﺳѧﺮﻃﺎﻧﺔ اﻟﺨﻠﻴѧﺔ اﻟﻈﻬﺎرﻳѧﺔ 
وﻣﻊ ذﻟﻚ ﻟﻢ ﺗﻮﺟﺪ ﻋﻼﻗﺔ ذات ﻣﻐﺰى ﺑﻴﻦ ﺗﺪﺧﻴﻦ اﻟﺘﺒﻎ وﺳѧﺮﻃﺎﻧﺔ اﻟﺨﻠﻴѧﺔ  
هѧﺬﻩ اﻟﻨﺘѧﺎﺋﺞ ﺗّﻤѧﺖ ﻣﻘﺎرﻧﺘﻬѧﺎ ﻣѧﻊ ﻧﺘѧﺎﺋﺞ دراﺳѧﺎت   (. P  =572.0)اﻟﻌﺎﺑﺮة 
  . ﻣﺸﺎﺑﻬﺔ ﻣﻦ دول اﺧﺮى
 أﻋѧѧﺪاد أورام اﻟﻤﺜﺎﻧѧѧﺔ اﻟﺒﻮﻟﻴѧѧﺔ ﻟѧѧﻰ أنﱠإوﻟﻘѧѧﺪ ﺧُﻠѧѧﺼﺖ هѧѧﺬﻩ اﻟﺪراﺳѧѧﺔ 
 اﻟѧﺴﻮدان ﻳѧﺸﺎرك ﺑﻌѧﺾ اﻟѧﺪول اﻟﻨﺎﻣﻴѧﺔ اﻻﺧѧﺮى  و أنﱠ ،اﻟﺨﺒﻴﺜﺔ ﻓﻰ زﻳﺎدة 
ﺌﻴѧﺔ و ﻳѧﺸﺎرك اﻟѧﺪول اﻟﻤﺘﻘﺪﻣѧﺔ ﻓѧﻰ ﺧѧﺼﺎﺋﺺ ﻓѧﻰ ﺑﻌѧﺾ اﻟﺨѧﺼﺎﺋﺺ اﻟﺒﻴ
َﻠѧﺔ ﻋѧﺪد اﻟﻤﺮﺿѧﻰ ﻠﻊ ﻓѧﻲ ﻗ ِ و اﻟﺘﺴﺠﻴﻞ ﻟﻪ ﺿ ِﺳﻮء ﺣﻔﻆ اﻟﺴﺠﻼت . أﺧﺮى
هﻨﺎﻟѧﻚ ﺣﻮﺟѧﺔ ﻟﺪراﺳѧﺔ ﺷѧﺎﻣﻠﺔ ﻟﻤﻌﺮﻓѧﺔ اﻻﻧﺘѧﺸﺎر . اﻟѧﺬﻳﻦ ﺷѧﻤﻠﺘﻬﻢ اﻟﺪراﺳѧﺔ
اﻟﺤﻘﻴﻘﻲ و ﻋﻮاﻣﻞ اﻟﺨﻄﻮرة اﻟﻤﺮﺗﺒﻄﺔ ﺑﺄورام اﻟﻤﺜﺎﻧﺔ اﻟﺒﻮﻟﻴѧﺔ اﻟﺨﺒﻴﺜѧﺔ ﻓѧﻲ 
ﺤﻲ و ﻓﻮاﺋѧﺪ ﺑѧﺮاﻣﺞ هﻤﻴﺔ اﻟﺘﺜﻘﻴﻒ اﻟѧﺼﱢ و ﻗﺪ ﺗﻄَﺮﻗﺖ اﻟﺪراﺳﺔ ﻷ . اﻟﺴﻮدان
اﻟﻔﺤﺺ اﻟﻄﺒﻲ اﻟﺪوري ﻷورام اﻟﻤﺜﺎﻧﺔ اﻟﺒﻮﻟﻴﺔ اﻟﺨﺒﻴﺜﺔ ﻣﻦ أﺟѧﻞ اﻟﻮﺻѧﻮل 
    .إﻟﻰ ﻧﺘﺎﺋﺞ أﻓﻀﻞ
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1-1 Introduction 
       Neoplasms of the bladder pose biologic and clinical 
challenges. Despite significant   inroads into their origins and   
improved methods of diagnosis, they continue to exact a high toll 
in morbidity and mortality. Although there are improvements in 
detection and management of these neoplasms, the death toll 
remains at about 108, 310 annually worldwide.1 
        Carcinoma of the bladder is more common in men than in 
women, in industrialized than in developing nations, and in urban 
than in rural dwellers. About 80% of patients are between the ages 
of 50-80 years.2 
     About 95% of bladder tumours is of epithelial origin, the 
remainder being mesenchymal tumours. Most epithelial tumours 
are composed of urothelial (transitional) type cells, but squamous 
and glandular carcinomas also occur. Urothelial tumours represent 
about 90% of all bladder tumours. 
      There are two distinct precursor lesions to invasive urothelial 
carcinoma. The more common are the noninvasive papillary 
tumours which appear to arise from papillary urothelial 
hyperplasia.3 The other precursor lesion is flat urothelial 
carcinoma, which is simply referred to as carcinoma in situ (CIS). 
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         Many systems of grading urothelial neoplasms were 
proposed. A more recent classification, based on a consensus 
reached at a conference by the International Society of Urological 
Pathology (ISUP) in 1998, recognizes a rare benign papilloma, a 
group of papillary urothelial neoplasms of low malignant potential, 
and two grades of carcinoma (low and high grade). This system 
was adopted by the WHO in 2004. The staging system most 
commonly used is the TNM classification of bladder neoplasms. 
      A number of factors have been implicated in the causation of 
transitional cell carcinoma. Some of the more important 
contributors include; cigarette smoking, industrial exposure, 
Shistosoma haematobium, long-term use of analgesics and prior 
exposure of the bladder to radiation. How these influences induce 
cancer is unclear, but a number of genetic alterations have been 
observed in urothelial cell carcinoma.4, 5 
        Bladder tumours classically produce painless hematuria. 
Frequency, urgency, and dysuria occasionally accompany the 
hematuria. 
        Patients with urothelial tumours, whatever the grade, have a 
tendency to develop new tumours after excision, and recurrences 
may exhibit a higher grade. The risk of recurrence and progression 
is related to several factors, including tumour size, stage, grade, 
 3
multifocality, prior recurrence rate, and associated dysplasia and/or 
carcinoma in situ in the surrounding mucosa.6-11 
       Although cystoscopy and biopsy is the mainstay of diagnosis, 
carcinoma in situ that produces no or only subtle gross mucosal 
changes and early small papillary lesions may be difficult to detect. 
Of value in these circumstances are cytologic examinations and 
tests that detect the presence of various urine markers such as 
human complement factor H-related proteins, fibrin-fibrinogen 
degradation products, hyaluronidase, telomerase, mucins, nuclear 
matrix proteins, and DNA content.12-15 The later diagnostic 
approach for DNA content is effective in differentiating high-grade 
tumours from the benign ones and detecting aneuploid high-grade 
lesions when there is uncertainty as to diagnosis. 
     The treatment for bladder cancer depends on the grade, the 
stage, and whether the lesion is flat or papillary. For small localized 
papillary tumours that are not high grade, the initial diagnostic 
transurethral resection is all that is done. When a patient presents 
with multifocal bladder tumours, instillation of topical chemotherapy 
into the bladder, in the immediate postoperative period, can reduce 
the likelihood of tumour recurrence. Topical immunotherapy 
consisting of intravesical instillation of an attenuated strain of 
Mycobacterium tuberculosis called Bacillus Calmette-Guerin 
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(BCG) is performed in patients who are at high risk of recurrence.16 
Radical cystectomy is performed in certain infiltrative tumours. 
Advanced bladder cancer is treated by chemotherapy. 
 Cancer of the bladder is known to remain localized for a 
relatively long time before it spreads extravesically. Nevertheless, 
it has always been looked at as a killing disease in Sudan.17 
 The main reason for this pessimistic outlook is the poor 
shape and advanced stage at which our patients present, making 
any effective surgical treatment difficult.  
 This study shows the pattern of urinary bladder neoplasms in 
Sudan as reviewed in two urological centers as well as the 
National Health Laboratory with regards to age, sex, origin, risk 
factors, clinical presentation and the histopathological 
classification, in addition to verification of different therapeutic 
options and outcome. 
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1-2 Literature Review  
   1-2-1 Normal Anatomy, Embryology and Histology:  
        The urinary bladder is a hollow, mostly muscular organ that 
stores urine until ready for release. It is located in the pelvis and 
related to the prostate and seminal vesicles in the male and vagina 
and uterus in the female. It is divided into the following portions: 
superior surface (also known as dome) and covered by the pelvic 
parietal peritoneum, posterior surface (also known as base), and 
the two inferolateral surfaces. The trigone is located at the base of 
the bladder and is continuous with the bladder neck, in which the 
posterior and inferolateral wall converge to open into the urethra. 
The lymphatic drainage of the bladder is primarily through the 
external and internal iliac nodes; portions of the bladder neck 
region may drain to the sacral or common iliac nodes.18 
      The bladder develops mainly from the vesical part of the 
urogenital sinus, but its trigone region is derived from the caudal 
ends of the mesonephric ducts.19 The epithelium of the urinary 
bladder is entirely derived from endoderm of the urogenital sinus, 
whereas the lamina propria, muscularis propria, and adventitia 
develop from the surrounding splanchnic mesenchyme.20 
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       The walls of the bladder are composed of three main layers; 
the mucosa, muscularis propria, and adventitia. The mucosa is 
formed by the epithelium, lamina propria, and (rarely) a continuous 
or discontinuous muscularis mucosa. The epithelium of the bladder 
has been traditionally referred to as transitional, but the term 
urothelium is more informative and accurate.18 The urothelium of 
the contracted bladder is six to eight cells thick and those at the 
luminal surface are rounded or cupshaped. In the distended 
bladder the urothelium is much thinner and the cells are 
flattened.21 The major function of the urothelium is to allow 
distention in the urinary organs during urine accumulation and 
contraction during the emptying of the urinary passages without 
breaking the cell contacts in the epithelium. In addition, it forms an 
important osmotic barrier between urine and the underlying tissue 
fluid.22  
         The urothelium has three layers: superficial, intermediate, 
and basal. The superficial layer is made up of single row of large, 
epitheloid cells having an abundant eosinophilic cytoplasm and 
referred to as umbrella cells. In electron microscopy, it has 
characteristic hexagonally arranged subunits. The intermediate 
cells have a cuboidal to low columnar shape, oval nuclei with finely 
stippled chromatin, moderately abundant cytoplasm, and well 
 7
defined margins. The basal layer is made up of cuboidal cells that 
lie on a thin continuous basal lamina.18 
       The lamina propria is composed of loose connective tissue 
containing a rich vascular network, lymph vessels, and a few 
elastic fibers. A rather prominent collection of arteries and veins is 
present in the midportion of the lamina propria and divides this 
layer into inner and outer zones. Smooth muscle cells are present 
in association with these vessels, usually as isolated bundles, 
sometimes as a discontinuous thin layer, and rarely as a 
continuous layer (muscularis mucosa).These muscle bundles 
should not be confused with those of muscularis propria when 
evaluating the depth of invasion of a bladder neoplasm. The 
muscularis propria is divided into inner and outer longitudinal 
layers and a central circular layer; these are best individualized in 
the bladder neck region.18 
1-2-2 Epidemiology: 
 
        Bladder cancer is the seventh most common cancer world 
wide, with an estimated 260,000 new cases occurring each year in 
men and 76,000 in women.23 It is the second most common 
urological cancer, 24 with the highest incidence rates of bladder 
cancer in Western Europe, North America and Australia.     It 
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accounts for about 3.2 % of all cancers worldwide and is 
considerably more common in males than in females (ratio 
worldwide is about 3.2:1).23 
       The incidence of bladder epithelial    tumours in the United 
States has been steadily increasing during the past years and is 
now more than 57,000 new cases annually.25 
       In the kingdom of Saudi Arabia (KSA) genito-urinary cancer 
(GUC) accounts for 9.2% of all cancer cases in KSA and the 
common GUC is bladder cancer.26 Bladder cancer is the second 
most frequent cancer in Iraq in both sexes, 27 while urinary bladder 
malignant neoplasms account for only 8% of malignant neoplasms 
in Repuplic of Yemen.28 In African countries, poor record keeping 
may have contributed to the low number of patients enrolled in 
some studies.29 
        In Sudan male patients predominate in all groups with a male 
to female ratio of 5:1   and the commonest age of presentation is 
50 to 70 years old.30    The incidence, morbidity, and mortality rates 
associated with bladder cancer vary by country, ethnicity, gender 
and age.31 According to 1997 Surveillance , Epidemiology , and 
End Results data of the US National Cancer Institute, white 
persons had an incidence of 17.7 per 100,000 population while 
black persons had an incidence of 9.2 per 100,000 population . 
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Men have a risk that is at least three times greater than that of 
women. The age adjusted incidence for men was 28.2 per 100.000 
populations, and it was 7.5 per 100,000 populations for women. 
Moreover, the life time risk of receiving a diagnosis of bladder 
cancer is 3.40% for men and 1.18% for women. Between 1998 and 
1997, persons 65 years old had an incidence of 110.8 per 100.000 
population while younger persons had an incidence of only 6.4 per 
100.000 population .Statistically, the risk for 70 years old person is 
two to three times greater than that for a person 55 to 69 years old, 
and 15 to 20 times greater than for a person 30 to 54 years old.31 
       In terms of mortality, the World Health Organization estimated 
that 132,432 persons died of bladder cancer world wide in 2000.  
In the United States approximately 12,200 individuals died of 
bladder cancer in 2000 .Men accounted for about two thirds of 
these deaths. The age adjusted mortality rate for bladder cancer 
was 3.2 per 100,000 in 1997. White persons had an age– adjusted 
mortality rate of 3.3 persons per 100,000 while Black persons had 
a mortality rate of 3.1 persons per 100,000. Although, Black 
persons have a much lower incidence of bladder cancer, they 
appear to have a mortality rate comparable to that of White 
persons. This finding suggests that black persons may receive a 
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diagnosis at a later stage of diseases, indicating a worse 
prognosis.31 
1-2-3 Risk factors: 
     The risk factors for bladder cancer are both environmental and 
genetic. 
1-2-3-1 Environmental risk factors: 
Tobacco smoking: 
           Tobacco smoking is the major established and the number 
one environmental risk factor of bladder cancer. It is estimated that 
the risk of bladder cancer attributed to tobacco smoking is 66%for 
men and 30 % for women. The risk of bladder cancer in smokers is 
2.6 fold that of non- smokers.23 
         The risk increases with increasing duration of smoking, and 
for those with the longest history of smoking (60 years or more) 
reaches approximately   6 times in men and 5 times in women31. 
The length of time that a person smokes appears to be the most 
important predictor of the risk. The aromatic amines contained in 
cigarette smoke are most likely responsible for this increased 
risk.31The excess of risk is   observed also with increasing intensity 
of smoking (number of cigarettes per day) reaching maximum of 
about 3 for those smoking 40 or more cigarettes per day. The 
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increase of risk with the increasing duration and intensity of 
smoking is similar in both sexes. The risk of bladder cancer goes 
down after stopping smoking, and after 15 years cessation tends to 
be approximately that of non–smokers.23 
       The study of Zhang ZF, et al evaluated seventy three patients 
with bladder cancer for smoking history, occupational history, and 
chromosome 9 alterations. It supplies evidence suggestive of the 
link between smoking and chromosome 9 alterations in the 
etiology of bladder cancer and indicates that potential tumour 
suppressor genes on chromosome 9 may be involved in smoking-
related bladder carcinogenesis.32 
Occupational exposure: 
         Bladder cancer is associated with a number of occupations 
or occupational exposures. The first such association was 
observed in 1895 by Rehn who reported high rates of bladder 
cancer among men employed in the aniline dye industry.23 
Subsequent researches among dye workers identify the aromatic 
amines benzidene and 2-naphthylamine and possibly 1-
naphthylamine, as bladder carcinogens. Work–related contact with 
chemicals, such as benzene derivatives and arylamines, likely 
account for 25% of all bladder cancer cases. Persons with 
professions involving heavy exposure to dyes, rubbers, textiles, 
 12
and chemicals demonstrate a high incidence of bladder cancer.31 
Recently, a population-based case-control study on hair dye use 
was conducted in 1514 cases of bladder cancer and an equal 
number of matched control subjects. After adjustment for cigarette 
smoking, women using permanent hair dyes at least once per 
month had 2.1 fold increased risk of bladder cancer compared with 
non users. Risk increased further to 3.3 fold for women using hair 
dyes for 15 years or longer.31 
     Huncharek M. and Kupelnick B. examined the methodology of 
observational studies that explored an association between 
personal use of hair dyes products and the risk of bladder cancer 
using a general variance-based meta-analytic method. The 
sensitivity performed, yielded statistically significant summery 
relative risk (RRs) ranging from 1.22 (1.11, 1.51) to 1.50 (1.30, 
1.98), indicating that personal use of hair dye products increases 
bladder cancer risk by 22% to 50% vs. non-use.33 
 Phenacetin: 
       Several epidemiological studies indicate that chronic abuse of 
analgesics containing phenacetin greatly enhances the risk of 
developing urothelial cancer of the renal pelvis, ureter and bladder. 
The relative risk has been estimated in the range of 2.4 to more 
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than 6. Early cases have been reported from Scandinavia, 
Switzerland and Australia.23 
Medicinal drugs: 
      The cytostatic agent, cyclophosphamide has long been 
associated with the development of leukemia and lymphoma.  In 
addition, treatment with cyclophosphamide has been reported to 
be associated with an increased risk of squamous cell carcinomas 
and sarcomas, especially leiomyosarcomas. Similarly 
chlornphazine is associated with the development of bladder 
cancer.23 
Chronic infections: 
           A potentially causative agent, particularly in Africa, is 
Schistosoma haematobium.This parasite is presumed to cause 
cancer by invoking chronic inflammation and interfering with the 
metabolism of cigarette smoke-related bladder mutagens. 
Interestingly most cancers caused by schistosomiasis are 
squamous cell in origin and appear in younger patients.31  
         Some authors suggested an association between bladder 
cancer and urinary tract infection and urinary tract stones. The 
underlying mechanism may lead to chronic irritation of the bladder 
epithelium, which may increase bladder cancer risk.23       
 
 14
Arsenic: 
       Arsenic is used in pesticides and some regions with high 
concentrations of arsenic in drinking water show a high rate of 
bladder caner. Several studies showed that use of drinking water 
containing chlorination byproducts or contaminated by arsenic 
might increase risk of bladder cancer.23 Arsenic-contaminated 
water is a potential risk factor of bladder cancer (reported in 
Argentina, Chile, Bangladesh and Taiwan). An International 
Agency for Research of Cancer (IARC) Monographs Working 
Group reviewed in 2004 the relevant epidemiological studies and 
concluded that arsenic in drinking water is carcinogenic to humans 
(group 1) and that there is sufficient evidence that it cause urinary 
bladder cancer. Key evidence came from ecological studies in 
Chile and Taiwan (China) where large populations were exposed.23 
         Arsenic has been well documented as the major risk factor 
for black foot disease (BFD).34 BFD is a unique peripheral vascular 
disease that was endemic in the South Western Coast of Taiwan, 
where residents had consumed high-arsenic artesian well water for 
more than 50 years. Long-term arsenic exposure has also been 
reported to be associated with bladder cancer mortality in a base- 
response relationship. Yang CY and et al  implemented a tap water 
supply system in the early 1960s in the BFD endemic areas to 
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examine whether bladder cancer mortality decreases after  the 
improvement of the drinking water supply system through 
elimination of arsenic exposure from artesian well water . 
Standardized mortality rations (SMRs) for bladder cancer were 
calculated for the BFD endemic areas for the years 1971 -2000. 
The study results showed that mortality from bladder cancer 
declined gradually after the improvement of the drinking water 
supply system to eliminate arsenic exposure from artesian well 
water. Based on the reversibility criterion, this finding strengthened 
the likelihood of the observed association between arsenic 
exposure and bladder cancer being causal.34 
        Researchers are studying other possible connections to 
bladder cancer including coffee, artificial sweeteners such as 
saccharine, diesel exhaust, pelvic radiation and others. Some 
connections can be made, but the evidence is not conclusive. 
       Environmental factors that may potentially reduce the risk of 
bladder cancer include the following: vitamin A; vitamin C; 
increased fluid intake and a low fat, high fruit and vegetable diet.31  
1-2-3-2 Genetic factors: 
        Urothelial carcinoma is not considered a familial disease. 
However, several epidemiological studies showed that urothelial 
carcinomas have a familial component with a 1.5 to 2- fold 
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increased risk among first–degree relatives of patients.23 The 
cytogenetic and molecular alterations are heterogeneous. 
Importantly, coamplification and simultaneous over expression of 
multiple adjacent oncogenes is often seen and it provides cells 
with  significant growth advantages.23  
Chromosomal abnormalities: 
      Invasively growing urothelial bladder cancer is characterized by 
presence of a high number of genetic alterations involving multiple 
different chromosomal regions. Particularly common (occurring in 
30 % to 60% of tumors studied) are chromosome 9 monosomy or 
deletions of 9p and 9q as well as deletions of 17p, 13q, 11p, and 
14q. The chromosome 9 deletions are the only genetic changes 
that are present frequently in superficial papillary tumours and 
occasionally in noninvasive flat tumours. 2 
     Panani AD et al studied the nonracial aberrations   of 
chromosomes 9 and 11 detected by FISH in 35 Greek patients 
with primary bladder tumours. They observed numerical 
aberrations of chromosomes 9 in 23 out of 27 tumours (85.18%). 
Monosomy 9 was detected in 12 cases (44.45%) and polysomy in 
11 cases(40.74%).The statistical  analysis of their study showed 
that polysomy 9 was linked to histological stage (P=0.024) and 
grade(P=0.01) of the tumours, while   monosomy 9 was correlated 
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with tumour stage (P=0.050). Numerical aberrations of 
chromosome 11 were observed in 25 out of 35 cases (71.43%). 
Polysomy was detected in 24 cases (68.57%), while only one case 
(2.86%) had monosomy 11. Polysomy 11 were found mainly in 
high grade and advanced - stage tumours.35   
         Imad Fadl-Elmula, et al, explored the genetic alterations of 
73 bladder Transitional Cell Carcinomas (TCCs), using G-banding, 
spectral karyotyping, and FISH analysis. They concluded that the 
karyotypic profile of bladder TCCs is characterized by non-random 
chromosomal aberrations varying from one or few changes in low 
grade and early stage tumours to massively rearranged karyotypes 
in muscle invasive ones. They observed that the karyotypic profile 
is dominated by losses of chromosomal materials. 36 
            In another study, Fadl-Elmula, et al   also found that 
rearrangements of chromosome 9 resulting in loss of material from 
9p, 9q, or of the entire chromosome are the most frequent 
cytogenetic alterations. These observations are seen as the sole 
change as well as massively complex karyotypes, indicating that 
loss of Tumour Suppressor Genes (TSGs) from this chromosome 
is of major importance in urothelial carcinogenesis.37                                               
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Oncogenes:          
     Her2/neu is a transmembrane   receptor tyrosine kinase without 
a known ligand. Its activation occurs through interaction with other 
members of the Epidermal Growth Factor Receptor (EGFR) gene 
family. HER2 is amplified in 10-20% and over expressed in10-50% 
of invasively growing bladder cancers. Amplifications or deletions 
of the adjacent topisomerase 2 alpha (TOP2A) are present in 
about 23% of HER2-amplified cases. TOP2A is the target of 
anthracyclines. Thus, the anatomy of the 17q23 amplicon may also 
influence the response to cytotoxic therapy regimens.23  
       H-ras is the only member of the ras gene family with known 
importance in urinary bladder cancer. H-ras mutations are almost 
always confined to specific alterations within the codons 12, 13 
and 61. H-ras mutations have been reported in up to 45% of 
bladder cancers.23  
     The epidermal growth factor receptor (EGFR) is another 
member of the class II receptor family. (EGFR) is a 
transmembrane tyrosine kinase acting as a receptor for several 
ligands including epidermal growth factor (EGF) and transforming 
growth factor alpha. EGFR also severs as a therapeutic target for 
several drugs including small inhibitory molecules and antibodies. 
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EGFR is amplified in 3-5% and overexpresed in 30-50 of invasively 
growing bladder cancers.23 
     Cyclin- dependant kinases (CDKs) and their regulatory subunits 
are important promoters of the cell cycle. The cyclin D1 gene 
(CCND1) located at 11q13 is one of the most regionally amplified 
and over expressed oncogens in bladder cancer. About 10-20% of 
bladder cancers show gene amplification, and over expression has 
been reported in 30-50% of tumours.23 
Tumors suppressor genes: 
        One of the genes that provide a growth advantage to affected 
cells in case of reduced expression or inactivation is the TP53 
gene. It is located at 17q23 and encodes a 53KDa protein which 
plays a role in several cellular processes including cell cycle, 
response to DNA damage, cell death and revascularization. 
Mutations of the TP53 gene, mostly located in the central DNA 
binding position of the gene, are a hallmark of invasively growing 
bladder cancers.23 An online query of the International Agency for 
Research on Cancer (IARC) data base (R7version, September 
2002) at www.iarc fr/ p53 revaluated TP53 mutations in 40-60% of 
invasive bladder cancers.38                                                
 The retinoblastoma (RB1) gene product was the first tumor 
suppressor gene to be identified in human cancer. (RB1) which is 
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localized at 13q14 plays a crucial role in regulation of the cell 
cycle. Inactivation of (RB1) occurs in 30-80% of muscle invasive 
bladder cancers, most frequently as a consequence of 
heterozygous 13q deletions in combination with mutation of the 
remaining allele. A strong association has been found between 
(RB1) inactivation and muscle invasion.23 Phenotypically different 
bladder tumours exhibit different patterns of cell cycle regulators 
and this may explain why these tumours have different propensity 
to progress to invasive tumours.39 
1-2-4 Clinical course: 
      Hematuria or blood in urine is by far the most common 
symptom of bladder cancer. Eighty to ninety percent of patients 
have this finding, which may be gross or microscopic, on initial 
evaluation.31 Salwa Sir Elkhatim found that the main presenting 
symptom was    heamaturia occurring in 96% of Sudanese patients 
and it was described as total and painless in 82% of the cases.30 
Separately, individuals may note disturbances in their urinary 
habits. These include complaints of dysuria (painful urination), 
increased frequency, urgency of urination, or failed attempts to 
urinate. These symptoms are reported in about 20% of patients 
and could be indicative of early disease. Other findings, such as a 
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mass in the bladder or urethral obstruction are more suggestive of 
invasive disease. When the urethral orifice is involved, 
pyelonephritis may follow. Any systemic complaints   point to 
extensive metastasis of the disease.31     
      Patients with urothelial tumors what ever the grade, have 
tendency to develop new tumors after excision, and recurrences 
may exhibit a higher   grade. The risk of recurrences and 
progression is related to several factors including tumor size, 
stage, grade and multifocality, prior recurrence rate and associated 
dysplasia and/or carcinoma in situ in the surrounding mucosa. 
Recurrent tumors reflect new tumors in some cases, and in other 
instances they share the same clonal abnormalities as the initial 
tumor and represent a true recurrence of the initial as a result of 
shedding and implantation of the original tumor cells. 2 
      The most important factors for progression-free survival are 
grade, presence of lamina propria, and associated carcinoma in 
situ. Papillomas, papillary urothelial cancer yield a 98% 10-year 
survival rate regardless of the number of recurrences; only a few 
patients (<10%) experience progression of their disease to higher–
grade lesions. In contrast, only about 40% of individuals with a 
high grade cancer survive 10 years; the tumour is progressive in 
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65%. Aproximately 70% of patients with squamous cell carcinoma 
are dead within the year. 2 
      The clinical challenge with these neoplsms is early detection 
and adequate follow up.  
1-2-5 Diagnosis: 
      The clinical work up for potential bladder cancer should start 
with complete physical examination and history, with careful 
attention to the patient's smoking history, past history of 
schistosomiasis, use of phenacetin-containing analgesics and 
alkylating drugs and possible occupational exposures. 
         A urine analysis reveals heamaturia in the majority of cases. 
On occasion, it may be accompanied by pyuria. Azotemia may be 
present in a small number of cases associated with urethral 
obstruction. Anemia may be due to chronic blood loss which is 
usual or to replacement of the bone marrow with metastatic 
disease.  
       Exfoliated cells from normal and abnormal urothelium can 
readily be detected in voided urine specimens. Exfoliative cytology 
is of little practical value in the initial evaluation of most bladder 
tumors because of their   accessibility to formal biopsy. However it 
is most useful in the following situations: detection of tumours 
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associated with extensive chronic inflammation in which the biopsy 
may be negative because of sampling, carcinoma in situ, and 
carcinomas   hidden in bladder diverticulum. Specimens obtained 
from bladder irrigation are superior to those resulting from voided 
urine.18 
     The greatest value of urinary bladder cytology is in the follow-up 
evaluation of patients who have received surgical or 
radiotheraputic treatment for bladder carcinoma. In some cases 
the recurrence may not become clinically apparent until more than 
a year after the malignant cells have been detected in urine. 
       The most distinctive cytological features of transitional cell 
carcinoma, which can be useful for their recognition at a metastatic 
site, are the spindle, pyramidal, and racquet- like shape of the 
tumour cells, eccentric nuclei, and cytoplasmic evidence of both 
squamous and glandular differentiation (including endo-
cytoplasmic interfaces and intra cytoplasmic vacuoles).18 
     Topical and systemic therapeutic agents and treatment 
modalities such as thiotepa and mitomycin C, cyclophosphamide, 
BCG, radiotherapy, photodynamic and laser treatment, and gene 
therapy produce a host of changes and alterations in the bladder, 
some of them mimicking cancer. Pathologists must be aware that, 
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following these types of treatment, the clinical usefulness of urinary 
cytology is reduced.40 
Cytology is very sensitive in detecting higher-grade and 
stage cancers (82% to 90%), but is less sensitive in detecting 
superficial or well-differentiated lesions (50%), because the cells 
are very similar to those of normal bladder mucosa. Sensitivity of 
detection using exfoliated cells may be enhanced by flow 
cytometry.24 
        Although cystoscopy and biopsy are the mainstays of 
diagnosis, carcinoma   insitu that produces no or only subtle gross 
mucosal changes and early small papillary lesions may be difficult 
to detect. Of value in these circumstances are cytological 
examination and tests that detect the presences of various urine 
markers such as human complement factor H-related proteins, 
telomerase, fibrin-fibrinogen degradation products, mucins, CEA, 
hyaluronic acid, hyaluronidase, nuclear matrix proteins, and DNA 
contents. The predominant limitation of many of the tests 
measuring urine markers is their relatively low specificity, because 
positive test results may occur in conditions associated with injured 
endothelium.2      
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      Bladder cancers may be detected using intravenous 
urography, ultrasound computerized tomography, or magnetic 
resonance imaging where filling defects within the bladder are 
noted. However the presence of cancer is confirmed by cystoscopy 
and biopsy so imaging is useful primarily for evaluating the upper 
urinary tract and in staging the more advanced lesions.24 
       Flow cytometric and image analysis techniques have been 
developed for the evaluation of DNA abnormalities   in cytological 
specimens from the bladder. These have reached a degree of 
accuracy equivalent to that of conventional cytological 
examination.18 Bartoltti R et al compared the diagnostic accuracy 
of urinary cytology, urinary bladder cancer (UBC) markers,   and 
bladder tumor antigen (BTA), and microsattelite sequence 
alterations in 42 patients. Urinary cytology confirmed the presence 
of TCC in 13 (3%) of the studied patients. The BTA-t markers 
allowed the identification of 73.3% of cases with 50.20% 
specificity.  The UBC markers identified 63, 3% of cases with 
41.6% specificity. Microsatellite analysis permitted the    
identification of 83.3% of the tumors with 100% specificity. DNA 
demonstrated high sensitivity in patients affected by superficial 
(81.4%) or grade 1 (80%) tumors.41  
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     Grossman HB et al investigated whether a point-of-care 
proteomic test that measures the nuclear matrix protein NMP22 in 
voided urine could enhance detection of malignancy   in patients 
with risk factor or symptoms of bladder cancer.  On his study, the 
diagnosis of bladder cancer, based on cystoscopy with biopsy, was 
accepted as the reference standard. The performance of the 
NMP22 test was compared with voided urine cytology as an aid to 
cancer detection. Bladder cancer was diagnosed in 79 patients.  
The NMP22 assay was positive in 44 of 79 patients with cancer 
(sensitivity 55.7%; 95% confidence interval [CI], 44.1%-66.7%)   
whereas cytology test results were positive in 12 of 76 patients   
(sensitivity, 15.8%; 95%CI, 7.6%-24.0%).The specificity of the 
NMP22 assay was 85.7 %( 95%CI, 83.8%-87.6%) compared with 
99.2% for cytology. The proteomic marker detected 4 cancers that 
were not visualized during initial endoscopies, including 3 that 
were muscle invasive and 1 carcinoma in situ. It can be concluded   
that the non–invasive point-of-care assay for elevated urinary 
NMP22 protein can increase the accuracy of cytology, with test 
results available during the patient visit.42 
             Cystoscopy, a procedure in which a camera is inserted   
through the urethra with the patient under a local anesthetic, is 
performed after the IVP. Its purpose is to look for tumors and 
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irregularities in the bladder. The surgeon should record the number 
of tumors as well as their   location, size, and shape. Any reddened 
or hardened areas that could be indicative of carcinoma in situ also 
should be noted. During cystoscopy, bladder wash can be 
performed to obtain cells for cytological   evaluation.  
         Histologic examination of tissue, whether obtained by 
cystoscopically directed, random, or selected-site biopsies, is 
currently the primary means of detecting and monitoring bladder 
neoplasms. Depending on the amount of tissue available, histology 
can be used to gauge the extent of the process and evaluate its 
biological potential. The major limitation of histologic examination 
is inadequate sampling, although the inability to accurately 
determine the viability and future behavior of certain neoplastic 
lesions represent a further drawback. Even with adequate 
samples, accurate histologic evaluation may be impeded by 
suboptimal preparations. Details of cellular structure can be 
discerned in specimens fixed in phosphate-buffered formalin but 
are more easily appreciated in tissues fixed in zinc formalin or 
picric acid-based solutions such as Bouins΄s or Hollande΄s.43 
          Immunohistochemichally, transitional cell carcinomas, the 
commonest bladder cancer, express various keratin types. A 
difference in pattern has been noted among basal cells, transitional 
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cells and umbrella cells (when present).44There is consistent 
expression of CK20, in stark contrast with the morphologically 
similar transitional cell carcinoma of the ovary.45 The CK20 
positivity is particularly common and strong in the high grade-
tumours.46The coordinate expression of CK7 and CK20 is a 
particularly reproducible feature of transitional cell carcinoma,47 
and is usually maintained in the metastatic foci.48 An increased 
expression of CK8 and CK18 has been found at the interface 
between tumor and stroma.49 In general, the expression of CK18 is 
decreased in higher–grade and higher stage tumors but many 
exceptions occur.49Two relatively new useful markers for 
transitional cell carcinoma are thrombomodulin and uroplakin III. 
The former is very sensitive but not very specific (in that it also 
stains most squamous cell carcinomas and mesotheliomas), 
whereas the latter has a high degree of specificity but is only 
moderately sensitive.51, 52, 53 Other markers commonly expressed 
by these tumours are CEA and Cathepsin B (particularly in high 
grade lesions), 54, 55, 56 CA19-9, 57 CD15 (Leu-M1),58 survivin,59 and 
androgen reseptors.60 
      Some tumors are also immunoreactive for Human Chorionic 
Gonadotrophin (HCG), Human Placental Lactogen, and SP-1, 
especially in the most pleomorphic areas60, 61; this can occur in the 
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absence of morphologic evidence of trophoblastic differentiation by 
the tumour.  
       Deletion of ABO blood group antigens is a common finding in 
transitional cell carcinoma, particularly in those having high grade 
microscopic features. This alteration can only be evaluated in 
“secretor” individuals, whose urothelium normally express these 
markers.  A related abnormality is the expression of Lewis X 
antigen (which is absent in normal urothelium) in over 85% of 
transitional cell carcinoma regardless of tumor stage and grade.62 
Interestingly the loss of blood group antigens is often associated 
with an over expression of the epidermal growth factor receptor.63 
    The lack of ABO antigen expression in certain bladder tumours 
is due to the allelic loss of the ABO glycosyltransferase-encoding 
genes and in some of these tumours the loss involves the 
surrounding chromosomal region at 9q34.1-4.64  
The immunohistochemical expression of the extracelluler 
matrix (ECM) components tenascin, fibronctin, collagen type IV 
and laminin is measured by different studies and correlated with            
clinicopthological features to clarify the prognostic value of these 
molecules and their role in tumour progression. Ioachim E, et al, 
studied 103 tumour specimens, obtained during transurethral 
resection of bladder tumour (TURBT), immunohistochemically and 
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concluded that levels of tenascin might be valuable for predicting 
the risk of early recurrence.  The expression of tenascin, 
fibronectin and collagen type IV seems to be correlated with more 
aggressive tumour behavior. Furthermore, their interrelationship 
could indicate that they are involved in remodeling of bladder 
cancer tissue probably influencing tumour progression.64  
       The expression of angiopoietin-1 and -2 which are 
antagonistic angiogenic factors that regulate tumor growth were 
assessed immunohistochlemically by Oka N, et al in tissue 
sections from 52 transitional cell carcinomas of the bladder. 
Normal bladder specimens were also resected during each 
operation as controls. The expression angiopoietins were related 
to the clinico- pathological variables of the tumors. Positive 
immunostaining was detected in 18 samples (35%) for 
angiopoietin-1 and in 23 (44%) for angiopoietin-2. There was no 
significant difference in survival according to tumor angiopoietin-
1status in the patients, but in contrast the overall survival of 
patients with angiopoietin-2 positive tumor was significantly lower 
than those with angiopoietin-2 negative tumors(P<0.05). Positive 
angiopoietin-2 expression was significantly correlated with 
histological grade (P=0.026), histological stage (P=0.009) and poor 
prognosis (P<0.05).On multivariate analysis, positive angiopoitin-2 
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expression was an independent negative predictor for survival 
(P=0.042).These results suggests that angiopoietin-2 over 
expression is associated with tumour progression, thereby 
indicating a poor prognosis for some patients treated by surgical 
resection for bladder carcinoma.66 
      Ultrastructurally, high grade transitional cell carcinomas are 
accompanied by a decrease of specialized junctions. Pleomorphic 
microvilli are apparent by scanning electron microscopy regardless 
of tumour grade.18   
1-2-6 Classification of urinary bladder tumours: 
        About 95% of bladder tumors are of epithelial origin, the 
remainders being mesenchymal tumours *(WHO histological 
classification of tumours of the urinary tract). Most epithelial 
tumours are composed of urothelial (transitional) type cells and are 
thus interchangeably called urothelial or transitional tumours. 2 
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*WHO histological classification of tumours of the urinary tract 
 
Urothelial tumours                                           Neuroendocrine tumours 
Infiltrating urothelial carcinoma                          Small cell carcinoma 
   with squamous differentiation                         Carcinoid 
   with glandular differentiation                           Paragangilioma 
   with trophoblastic differentiation 
   Nested                                                            Melanocytic tumours 
   Microcystic                                                      Malignant melanoma  
   Micropapillary                                                 Nevus 
   Lymphoepithelioma-like  
   Lymphoma-like                                               Mesenchymal tumours 
   Plasmacytoid                                                  Rhabdomyosarcoma 
   Sarcomatoid                                                   Leiomyosarcoma 
   Giant cell                                                        Angiosarcoma 
   Undifferentiated                                             Osteosarcoma 
Non-invasive urothelial neoplasia                     Malignant fibrous histocytoma 
   Urothelial carcinoma in situ                            Leiomyoma 
   Non-invasive papillary urothelial                    Haemangioma 
      carcinoma, high grade                                Others 
   Non-invasive papillary urothelial  
      carcinoma, low grade                                 Haematopoitic and                                               
   Non-invasive papillary urothelial                       lymphoid tumours 
      neoplasia of low malignant Potential          Lymphoma 
   Urothelial papilloma                                       Plasmacytoma 
   Inverted urothelial papilloma 
                                                                         Miscellaneous tumours 
Squamous neoplasms                                   Carcinoma of skene, Cowper     
Squmous cell carcinoma                                     and Little glands 
Verrucous carcinoma                                       Metastatic tumours and tumours 
Squamous cell papilloma                                    extending from other organs 
 
Glandular neoplasms 
Adenocarcinoma 
   Enteric  
   Mucinous 
   Signet ring cell 
   Clear cell  
Villous adenoma 
 
 
 
 
 
 
 33
1-2-6-1 Urothelial (Transitional) cell tumours: 
      These represent about 90% of all bladder tumors. They run the 
gamut from small benign lesions that might never recur to 
aggressive cancers associated with high risk of death. Many of 
these tumors are multifocal at presentation. Although most 
commonly seen in the bladder any of the lesions may be seen at 
any site where there is urothelium; from the renal pelvis to the 
distal urethra. 2 
Morphologic features: 
        Urothelial tumors can arise anywhere in the bladder. In a 
series of about 1000 cases, the location was listed as follows: 
lateral walls, 37%; posterior wall, 18%; trigone,12%; neck 11%; 
ureteric orifices, 10%; dome,8%; and anterior wall,4%. They have 
also been reported within diverticula.67 
The pattern of growth may be exophytic or endophytic, or a 
combination of both. When exophytic, the tumour may adopt a 
papillary configuration (with central fibrovascular cores) or a solid 
(nodular) appearance. When growing endophytically (especially if 
well-differentiated), it may result in nested formations in the lamina 
propria, which may be under diagnosed as von Brunn’s nests 
cystitis glandularis/cystica. Stromal invasion by the tumour 
proceeds in two stages: invasion of the lamina propria and 
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invasion of the muscle layer. Detection of the former is a difficult 
somewhat subjective and relatively unimportant exercise. 
Conversely, detection of muscle invasion is of great consequence 
because of its influence on therapy and prognosis.18  
         There are two distinct precursor lesions to invasive urothelial 
carcinoma. The more common are non-invasive papillary tumours, 
which appear to arise from urothelial   dysplasia.3 Urothelial 
dysplasia has appreciable loss of polarity with nuclear rounding 
and crowding and cytologic atypia that is not severe enough to 
merit a diagnosis   of carcinoma in situ. The other precursor lesion 
is flat urothelial carcinoma, which is simply referred to as 
carcinoma in situ (CIS).2  
Grading of urothelial tumours: 
        Several classification systems of bladder transitional cell 
carcinoma have been proposed over the years. These represent 
attempts at grading the increasing degrees of architectural and 
particularly cytological disarrays of a single tumor type.   
         The first widely used grading system for these tumours was 
that proposed by Ash in 1940. He thought that even the better 
differentiated papillary tumors should be classified as carcinoma 
because of their tendency to recur locally and also because the 
microscopic pattern does not always conform to the clinical 
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behavior, a fact that recent series have confirmed.   The alternative 
terminology proposed by Mostofi in 1960 and adopted by the 
American Bladder Tumour Registry and the WHO in 1973, grades 
tumours into a rare totally benign papilloma and three grades of 
transitional cell carcinoma (grade I, II, and III). A more recent 
classification, based on a consensus reached at  a conference by 
the International Society of Urological pathology (ISUP) in 1998, 
recognizes a rare benign papilloma, a group  of papillary urothelial 
neoplasms of low malignant potential, and two grades of 
carcinoma (low and high grade).   Its main features are the division 
of the neoplastic lesions into flat and papillary and the separate 
evaluation of the papillary neoplasms for grade (based on 
architecture and cytology) and invasiveness (divided into lamina 
propria and muscularis propria levels).18  
        The presently recommended nomenclature by the WHO is 
similar to the WHO/ISUP classification of 1998, but the diagnostic 
criteria are further defined for practice. The terms non-invasive 
have been added to low and high grade papillary carcinoma to 
emphasize biologic differences between these tumours and 
infiltrating urothelial cancer.23 
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Non-invasive urothelial tumours: 
Urothelial papilloma: 
       Exophytic urothelial papilloma is composed of a delicate 
fibrovascular core covered by urothelium indistinguishable from 
that of the normal urothelium. It represents 1-4% of bladder 
tumours, most commonly seen in younger patients. The tumour 
usually arises singly as small (0.5-2.0 cm), delicate   structures, 
superficially attached to the mucosa by a stalk. Urothelial 
papillomas rarely recur. Histologically, the lesion is characterized 
by discrete papillary fronds, with occasional branching in some 
cases, but without fusion. The stroma may show edema and or 
scattered inflammatory cells, the epithelium lacks atypia and the 
superficial cells (umbrella cells) are often prominent. Mitoses are 
absent to rare and, if present are basal in location and not 
abnormal. The lesions are diploid, mitoses rare and proliferation 
rates low as deemed by immunohistochemical assessment of e.g. 
Ki-67 expression. Cytokeratin 20 expression is identical to that in 
normal urothelium i.e. in the superficial (umbrella) cells only.23 
         Inverted papilloma is a benign urothelial tumour that has an 
inverted growth pattern with normal to minimal cytologic atypia of 
the neoplastic cells. Histologically, anastamosing islands and cords 
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of uniform width and distribution appear as if a papillary lesion had 
invaginated into the lamina propria.23   
Papillary urothelial neoplasm of low malignant potential 
(PUNLMP): 
    This  is a papillary urothelial tumour which resembles the 
exophytic urothelial papilloma, but shows increased cellular 
proliferation exceeding the thickness of normal urothelium. The 
incidence is three cases per 100.000 individuals per year. 
Histologically, the papillae are discrete, slender and none fused 
and are lined by multilayered urothelium with minimal to absent 
cytologic atypia. The cell density appears to be increased 
compared to normal. The polarity is preserved and there is an 
impression of predominant order with absent to minimal variation in 
architectural and nuclear features. The nuclei are slightly enlarged 
compared to normal. The basal layers show palisading and the 
umbrella cell layer is often preserved. Mitoses are rare and have a 
basal location. The tumours are predominantly diploid. PUNLMP 
may recur with the same morphology, are not associated with 
invasion, and only rarely recur as higher-grade tumours associated 
with invasion and progression.  
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Non-invasive papillary urothelial carcinoma, low grade: 
        Is a neoplasm of urothelium lining papillary fronds which show 
an orderly appearance, but easily recognizable variations in 
architecture and cytologic features. The incidence is five cases per 
100,000 individuals per year. Histologically, the tumour is 
characterized by slender, papillary stalks which show frequent 
branching and minimal fusion. It shows an orderly appearance with 
easily recognizable variations in architectural and cytologic 
features even at scanning power. In contrast to PUNLMP, it is easy 
to recognize variations in nuclear polarity, size, shape, and 
chromatin pattern. The nuclei are uniformly enlarged with mild 
differences in shape, contour and chromatin distribution. Nucleoli 
may be present but inconspicuous. Mitoses are infrequent and 
may occur at any level but are more frequent basally. Expression 
of cytokeratin 20, CD44, p53 and p63 immunostaining is 
intermediate between that of PUNLMP and non-invasive high 
grade papillary urothelial carcinoma. The tumours are usually 
diploid. Recurrence is common and occurs in 48-71% of the 
patients. Progression to invasion and cancer death occurs in less 
than 5% of cases.23  
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Non-invasive papillary urothelial carcinoma, high grade: 
     Is a neoplasm of urothelium lining papillary fronds which show a 
predominant pattern of disorder with moderate-to-marked 
architectural and cytologic atypia. Histlogically, the tumour is 
characterized by a papillary architecture in which the papillae are 
frequently fused and branching, although some may be delicate. It 
shows a predominant pattern of disorder with easily recognizable 
variations in architectural and cytologic features even at scanning 
power. In contrast to non-invasive low grade papillary urothelial 
carcinoma, it is easy to recognize more marked variations in 
nuclear polarity, size,   shape, and chromatin pattern. The nuclei 
often show pleomorphism with moderate–to-marked variation in 
size and irregular chromatin distribution. Nucleoli are prominent. 
Mitoses are frequent, may be atypical, and occur at any level, 
including the surface. The thickness of the urothelium may vary 
considerably and often with cell dyscohesion. Detection of 
cytokeratin 20, p53, and p63 is more frequent than in low grade 
tumours. The tumours are usually aneuploid.23 
Urothelial carcinoma in situ (CIS): 
       Urothelial carcinoma in situ is defined as a non-papillary, i.e. 
flat lesion in which the surface epithelium contains cells that are 
cytologically malignant.23 This lesion is by definition high grade and 
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hence not assigned a grade.2 De novo (primary) carcinoma in situ 
accounts for less than 1-3% of urothelial neoplasms, but is seen in 
45-65% of invasive urothelial carcinoma. It is present in 7-15% of 
papillary neoplasms.68 Macroscopically, the mucosa may be 
unremarkable or erythematous and edematous. Mucosal erosion 
may be present. Histologically, urothelial carcinoma in situ shows 
nuclear anaplasia identical to high grade urothelial carcinoma. The 
enlarged nuclei are frequently pleomorphic, hyperchromatic, and 
have a coarse or condensed chromatin distribution; they may show 
large nucleoli. Mitoses including atypical ones are common and 
can extend to the upper cell layers. The cytoplasm is often 
eosinophilic or amphophilic. There is loss of cell polarity with 
irregular nuclear crowding.69, 70The neoplastic change may or may 
not involve the entire thickness of the epithelial layer and umbrella 
cells may be present. It may be seen at the basal layer only or may 
overly benign appearing epithelium. Individual cells or clones of 
neoplastic cells may be seen scattered amidst apparently normal 
urothelial cells and this is referred to as pagetoid spread.71 
 Infiltrating urothelial carcinoma: 
     Infiltrating urothelial carcinoma is defined as a urothelial tumour 
that invades beyond the basement membrane. The histology of 
infiltrating urothelial carcinoma is variable. These carcinomas are 
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graded as low grade and high grade depending upon the degree of 
nuclear anaplasia and some architectural abnormalities. Some 
cases may show relatively bland cytology. 
       The most important element in pathologic evaluation of 
urothelial cancer is recognition of the presence and extent of 
invasion. In early invasive urothelial carcinomas, foci of invasion 
are characterized by nests of, clusters, or single cells within the 
papillary cores and/or lamina propria. It is recommended that the 
extent of lamina propria invasion in pT1 tumor should be stated. 
The depth of lamina propria invasion is regarded as a prognostic 
parameter in pT1 cancer.  Morphologic criteria useful in assessing 
of lamina propria invasion include the presence of desmoplastic 
stromal response, tumor cells within the retraction space, and 
paradoxical differentiation (invasive nests of cells with abundant 
eosinophilic cytoplasm at the advancing edge of infiltration). 
Recognition of invasion may be problematic because of tangential 
sectioning, thermal and mechanical injury, marked inflammatory 
infiltrates obscuring neoplastic cells and inverted or broad front 
growth.23   
    The histology of infiltrative urothelial carcinoma has no specific 
features and shows infiltrating cohesive nests of cells with 
moderate to abundant amphophilic cytoplasm and large 
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hyperchromatic nuclei. In larger nests, palisading of nuclei may be 
seen at the edges of the nests. The nucleus is typically 
pleomorphic and often has irregular contours with angular profiles. 
Nuclei are highly variable in number and appearance with some 
cells containing single or multiple nucleoli and others having large 
eosinophilic nucleoli. Foci of marked pleomorphism may be seen, 
with bizarre and multinuclear tumor cells. Mitotic figures are 
common, with numerous abnormal forms. The invasive nests 
usually induce a desmoplastic stromal reaction which is 
occasionally pronounced and may mimic a malignant spindle cell 
component, a feature known as pseudosarcomatous stromal 
reaction.23 
Histologic variants: 
      Urothelial carcinoma has a propensity for divergent 
differentiation with the most common being squamous followed by 
glandular. Virtually the whole spectrum of bladder cancer variants 
may be seen in variable proportions accompanying otherwise 
typical urothelial carcinoma. Divergent differentiation frequently 
parallels high grade and high stage urothelial cancer. When small 
cell differentiation is present, even focally, it portends a poor 
prognosis and has different therapeutic ramifications, and hence 
should be diagnosed as small cell carcinoma.23 
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Infiltrating urothelial carcinoma with squamous 
differentiation: 
      Squamous differentiation, defined by the presence of 
intercellular bridges or keratinization, occurs in 21% of urothelial 
carcinoma of the bladder. Its frequency increases with grade and 
stage. Detailed histologic maps of urothelial carcinoma with 
squamous differentiation have shown that the proportion of the 
squamous component may vary considerably, with some cases 
having urothelial carcinoma in situ as the only urothelial 
component. The diagnosis of squamous cell carcinoma is reserved 
for pure lesions without any associated urothelial component, 
including urothelial carcinoma in situ. Tumours with any identifiable 
urothelial element should be classified as urothelial carcinoma with 
squamous differentiation and an estimate of the percentage of 
squamous component should be provided. Squamous 
differentiation may show basaloid or clear cell features. Cytokeratin 
14 and L1 antigen have been reported as immunohistochemical 
markers of squamous differentiation. Uroplakins are expressed in 
urothelial carcinoma and not in squamous differentiation.23  
        The clinical significance of squamous differentiation remains 
uncertain, but seems to be an unfavorable prognostic feature in 
such patients undergoing radical cystectomy, possibly, because of 
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its association with high grade tumors. Squamous differentiation 
was predictive of a poor response to radiation therapy and possibly 
also to systemic chemotherapy.23 
Infiltrating urothelial carcinoma with glandular differentiation: 
     Glandular differentiation is less common than squamous 
differentiation and may be present in about 6% of ureothelial 
carcinomas of the bladder. Glandular differentiation is defined as 
the presence of true glandular spaces within the tumour. These 
may be tubular or enteric glands with mucin secretion. A colloid 
mucinous pattern characterized by nests of cells floating in 
extracellular mucin occasionally with signet ring cells may be 
present. Pseudoglandular spaces caused by necrosis or artifact 
should not be considered evidence of glandular differentiation. 
Cytoplasmic mucin containing cells are present in 14-63% of 
typical urothelial carcinoma and not considered to represent 
glandular differentiation. The diagnosis of adenocarcinoma is 
reserved for pure tumors. A tumour with mixed glandular and 
urothelial differentiation is classified as urothelial carcinoma with 
glandular differentiation and an estimate of   the percentage of 
glandular component should be provided. The expression of 
MUC5AC-apomucin may be useful as immunohistochemichal 
marker of glandular differentiation in urothelial tumours. The 
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clinical significance of glandular differentiation and mucin positivity 
in urothelial carcinoma remains uncertain. 
Nested variant: 
      The nested variant of urothelial carcinoma is an aggressive 
neoplasm with less than 50 reported cases.23 There is marked 
male predominance, and 70% of patients died 4-40 months after 
diagnosis, in spite of therapy. This rare pattern of urothelial 
carcinoma was first described as a tumor with a deceptively benign 
appearance that closely resembles von Brunn nests infiltrating the 
lamina propria. Some nests have small tubular lumens. Nuclei 
generally show little or no atypia, but invariably the tumor contains 
foci of unequivocal anaplastic cells exhibiting enlarged nuclei and 
course nuclear chromatin. This feature is most apparent in deeper 
aspects of the tumour. Useful features in recognizing this lesion as 
malignant are the tendency for increasing cellular anaplasia in the 
deeper aspects of the lesion, its infiltrative nature, and the frequent 
prescience of muscle invasion.23 Moreover, immunohistochemical 
studies showed nested variant of urothelial carcinoma to have 
higher MIB-1expression than florid von Brunn nests (8.8% vs. 
2.8%, P=0.01).72 
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Microcystic variant: 
       Occasionally urothelial carcinoma shows a striking cystic 
pattern with cysts ranging from microscopic up to 1-2 mm in 
diameter. The cysts are round to oval, sometimes elongated and 
may contain necrotic material or pail pink secretions. The cyst 
lining may be absent, flattened or urothelial and may show  
differentiation towards mucinous cells.23 
Micropapillary variant:  
        Micropapillary bladder carcinoma is a distinct variant of 
urothelial carcinoma that resembles papillary serous carcinoma of 
the ovary, and approximately 60 cases were reported in the 
literature. There is a male predominance and patients age range 
from fifth to ninth decades with a mean age of 66 years. 
Histologically, micropapillary growth pattern is almost always 
associated with conventional urothelial carcinoma or rarely with 
adenocarcinoma.The micropapillary pattern exhibits two distinct 
morphologic features. Slender delicate fine papillary and filiform 
processes, often with a central vascular core, are observed on the 
surface of the tumours. On  cross section they exhibit a 
glomeruloid appearance. In contrast, the invasive portion is 
characterized by tiny nests of cells or slender papillae, which are 
contained within tissue retraction spaces that simulate lymphatic 
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spaces. However, in most cases vascular/lymphatic invasion is 
present. The individual cells of micropapillary carcinoma show 
nuclei with prominent nucleoli and irregular distribution of the 
chromatin. Also, the cytoplasm is abundant, eosinophilic or clear, 
and mitotic figures range from few to numerous. 
     Immunohistochemical studies in one large series disclosed 
immunoreactivity of the micropapillary carcinoma in 20 of 20 cases 
for EMA, cytokeratin (CK) 7, CK 20, and Leu M 1. CEA was 
positive in 13 of 20 cases. Micropapillary carcinoma is a high 
grade, high stage variant of urothelial cancer with high incidence of 
metastases and morbidity.23 
        Carcinomas with a micropapillary component are 
morphologically identical in breast, urinary bladder and lung. 
Immunohistochemical stains are useful in distinguishing these 
lesions in that thyroid transcription factor-1 positivity suggests a 
lung primary, CK7 and estrogen receptor suggest a breast primary, 
and both CK7 and CK20 positivity suggest a urinary bladder 
primary.73 
Lymphoepithelioma-like carcinoma: 
     Carcinoma that histologically resembles lymphepithelioma of 
the nasopharynx has recently been described in the urinary 
bladder, with fewer than 40 cases reported.74 These tumours are 
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more common in men than in women (10:3, ratio) and occur in late 
adulthood (range 52-81 years, mean 69 years).The 
etiopathogenesis of this tumor is unknown, although it is suspected 
that it originate from modified urothelial cells, that are possibly 
derived from basal (stem) cells. Hybridization with Epstein-Barr 
virus encoded RNA has been reported to be consistently negative 
in different series. The tumor is solitary and usually involves the 
dome, posterior wall, or trigone. 
       Lymphepithelioma-like carcinoma may be pure, predominant 
or focally admixed with typical urothelial carcinoma, or in some 
cases with squamous cell carcinoma or adenocarcinoma.43 
Histologically, the tumor is composed of nests, sheets, and cords 
of undifferentiated cells with large pleomorphic nuclei and 
prominent nucleoli. The cytoplasmic borders are poorly defined 
imparting a syncytial appearance. The background consists of a 
prominent lymphoid stroma that includes T and B lymphocytes, 
plasma cells, histocytes, and occasional neutrophils or eosinophils, 
the later being prominent in rare cases. The epithelial cells of this 
tumor stain with several cytokeratin (CK) markers as follows: 
AE1/AE3, CK8, CK7, and they are rarely positive for CK20.74 
Differentiation from lymphoma may be difficult, but the presence of 
a syncytial pattern of large malignant cells with a dense 
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polymorphous lymphoid background is an important clue. Most 
reported cases of the urinary bladder had a relatively favorable 
prognosis when pure or predominant, but when lymphepithelioma-
like carcinoma is focally present in an otherwise typical urothelial 
carcinoma, these patients behave like patients with conventional 
urothelial carcinoma alone of the same grade and stage.74 This 
tumor, thus far has been found to be responsive to chemotherapy 
when it is encountered in its pure form. 
Lymphoma-like and plasmacytoid variants: 
    The lymphoma-like and plasmacytoid variants of urothelial 
carcinoma are those in which the malignant cells resemble those 
of malignant lymphoma or plasmacytoma. Less than 10 cases 
have been reported. The histologic features of the lymphoma-like 
and plasmacytoid variants of urothelial carcinoma are 
characterized by the presence of single malignant cells in a loose 
or myxoid stroma.The tumour cells have clear or eosinophilic 
cytoplasm and eccentrically placed, enlarged hyperchromatic 
nuclei. Almost all of the reported cases have had a component of 
high grade urothelial carcinoma in addition to the single malignant 
cells. The tumour cells stain with cytokeratin (CK) cocktail, CK7and 
CK 20. Immunohistochemical stains for lymphoid markers have 
consistently been reported as negative.23 
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Sarcomatoid variant: 
     The term sarcomatoid variant of urothelial carcinoma should be 
used for all biphasic malignant neoplasms exhibiting morphologic 
and/or immunohistochemical differentiation. Microscopically, 
sarcomatoid carcinoma is composed of urothelial, glandular or 
small cell component showing variable degrees of differentiation. 
The mesenchymal component most frequently observed is an 
undifferentiated high grade spindle cell neoplasm. By 
immunohistochemistry, epithelial elements react with cytokeratins, 
whereas stromal elements react with vimentin or specific markers 
corresponding to mesenchymal differentiation. The sarcomatoid 
phenotype retains the epithelial nature of the cells by 
immunohistochemistry or electron microscopy. Recent molecular 
studies, strongly argue for a monoclonal origin of both 
components. Nodal and distant metastases at diagnosis are 
common and 70% of patients died of cancer at 1 to 48 months 
(mean 17 months).75 
Urothelial carcinoma with giant cells: 
       High grade urothelial carcinoma may contain epithelial tumour 
giant cells or the tumor may appear undifferentiated resembling 
giant cell carcinoma of the lung. This variant is very infrequent.23 
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Urothelial carcinoma with trophoblastic differentiation: 
       Trophoblastic differentiation in urothelial carcinoma occurs at 
different levels. High grade invasive urothelial carcinomas may 
express ectopic human chorionic gonadotrophin (HCG) and other 
placental gonadotrophins at the immunohistochemical level only or 
may contain numerous syncytotrophoblastic giant cells.23 
Clear cell variant: 
     The clear cell variant of urothelial carcinoma is defined by a 
clear cell pattern with glycogen-rich cytoplasm. The clear cell 
patter may be focal or extensive and awareness of this pattern is 
important in differential diagnosis with clear cell adenocarcinoma of 
the urinary bladder and metastatic carcinoma from the kidney and 
prostate.76 
Lipid cell variant: 
    Very infrequently urothelial carcinomas contain abundant lipid in 
which lipid distended cells mimic signet ring cell adenocarcinoma. 
Undifferentiated carcinoma: 
   This category contains tumours that can not be otherwise 
classified. They are extremely rare.  
 
 
 52
1-2-6-2 Squamous cell carcinoma: 
      This is defined as a malignant neoplasm derived from the 
urothelium showing histologically pure squamous phenotype. 
      Squamous cell carcinoma (SQCC) of the bladder is much less 
frequent than urothelial carcinoma. Worldwide, it constitutes about 
1.3% of bladder tumours in males, and 3.4% in females. SQCC 
accounts for approximately 5% of bladder carcinomas in areas 
where schistosomiasis is not endemic, although in some series 
higher figures in the range of 10-15% have been obtained. 
However, SQCCs comprise approximately 75% of bladder tumours 
where schistosomiasis is endemic. The male: female ratio is lower 
than it is in cases of transional cell carcinoma but the age 
distribution is similar.77 In the United States, the differences in 
histology by race are small, with, Whites having 95% urothelial and 
1.3% squamous cell carcinomas (SQCCs), while the proportions 
are 87.8% and 3.2%, respectively, in Blacks.23 In Africa, the 
majority of bladder cancers in Algeria and Tunisia (high incidence 
countries) are urothelial carcinomas, with SQCCs comprising less 
than 5%. In some West African countries (Mali, Niger), and in east 
and south-east Africa (Zimbabwe, Malawi, Tanzania), SQCC 
predominates, as it does in Egypt. In South Africa, there are 
marked differences in histology between Blacks (36% SQCC, 41% 
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urothelial) and Whites (2% SQCC, 94% urothelial). These 
observations (as well as clinical features such as sex ratio, mean 
age at diagnosis and stage) relate to the prevalence of infection 
with Schistosoma haematobium.23 
Schistosomiasis and SQCC: 
     The evidence linking infection with Schistosoma haematobium 
with bladder cancer has been extensively reviewed. There are 
essentially three lines of evidence: 
     The first one is the clinical observations that the two diseases 
appear to frequently co-exist in the same individual, and that the 
bladder cancers tend to be of squamous cell origin rather than 
urothelial carcinomas. Secondly, many descriptive studies show a 
correlation between the two diseases in different populations. 
Thirdly, the different case-control studies, comparing infection with 
S. haematobium in bladder cancer cases and control subjects. 
Several studies investigated this relationship, taking as a measure 
of infection the presence of Schistosoma haematobium eggs in a 
urine sample, presence of calcified eggs identified in X-ray or 
information from a questionnaire. The estimated relative risk varied 
from 2 to 15 compared with non-infected subjects.23 
        Numerous explanations have been offered for the proposed 
association between schistosomiasis and human cancer:  
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      Chronic infection and inflammation with increased cell turnover 
provide opportunities for mutagenic events, genotoxic effects and 
activation of carcinogens through several mechanisms, including 
the production of nitric oxide by inflammatory cells (activated 
macrophages and neutrophils). Altered metabolism of mutagens 
may be responsible for genotoxic effects. Quantitatively altered 
tryptophan metabolism in Schistosoma haematobium-infected 
patients result in higher consentrations of certain metabolites (e.g. 
indicant, anthranilic acid glucuronide, 3-hydroxyanthranilic acid, L-
kynurenin, and others) in pooled urine. Some of these metabolites 
have been reported to be carcinogenic to the urinary bladder. 
Immunological changes have been suggested as playing a role.  
     Furthermore, secondary bacterial infection of schistosoma-
infected bladders is a well documented event, and may play an 
intermediary role in the geneses of squamous cell carcinoma via a 
variety of metabolic effects. Nitrate, nitrite and N-nitroso 
compounds are detected in the urine of S.haematobium-infected 
patients. Nitrosamines are formed by nitrosation of secondary 
amines with nitrites by bacterial catalysis (or via urinary phenol 
catalysis); they may be carcinogenic to bladder mucosa. In 
addition, elevated levels of β-glucuronidase levels in schistosme-
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infected subjects could increase the release of carcinogenic 
metabolites from their glucuronides.23 
       Genetic damage in the form of slightly increased sister 
chromatid exchange and micronucleus frequencies were seen in 
peripheral blood lymphocytes harvested from schistosomiasis 
patients, and micronuclei were more frequent in urothelial cells 
from chronic schistosomiasis patients than in controls. 
       Lundgren R, et al investigated SQCC cytogenetically by 
means of chromosome banding and they found a complex 
karyotype with many structural and numerical changes, including -
9 and del (11p), aberrations that also have been noted in 
transitional cell carcinoma.78 
      Macroscopically, most squamous cell carcinomas are bulky, 
polypoid, solid, necrotic masses, often filling the bladder lumen. 
     Histologically, the diagnosis of squamous cell carcinoma is 
restricted to pure tumours.79 The presence of keratinizing 
squamous metaplasia in the adjacent flat epithelium, especially if 
associated with dysplasia, supports a diagnosis of squamous cell 
carcinoma. 
      The invasive tumours may be well differentiated with well 
defined islands of squamous cells with keratinization, prominent 
intercellular bridges, and minimal nuclear pleomorphism. They may 
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also be poorly differentiated, with marked nuclear pleomorphism 
and only focal evidence of squamous differentiation.23 A basaloid 
pattern has been reported.80 
Prognostic and predictive factors: 
        Patient related factors, e.g. sex and age are not prognostic in 
squamous cell bladder cancer. In contrast, T-stage, lymph node 
involvement and tumour grade have been shown to be of 
independent prognostic value. Patients undergoing radical surgery 
appear to have an improved survival as compared to radiation 
therapy and/or chemotherapy, while neoadjuvant radiation 
improves the outcome in locally advance tumours. 
      Pathologic stage is the most important prognostic parameter 
for squamous cell carcinoma. The tumours are staged using the 
TNM system as for urothelial carcinoma. In a series of 154 
patients, overall 5-year survival was 56%; for those patients with 
organ-confined tumour (pT1, 2) it was 67% and for non organ-
confined (pT3, 4) it was only 19%. 
      There are no uniformly accepted criteria for grading of 
squamous cell carcinoma. Squamous cell carcinoma of the bladder 
has been graded according to the amount of keratinization and the 
degree of nuclear pleomorphism.79 
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       Verrucous carcinoma is an uncommon variant of squamous 
cell carcinoma that occurs almost exclusively in patients with 
schistosomiasis, accounting for 3% to 4.6% of bladder cancers. It 
has a good prognosis.23 
        Sqamous cell papilloma of the urinary bladder is a very rare 
benign, proliferative squamous lesion. It occurs in elderly women 
without specific clinical symptoms. It is not associated with human 
papilloma virus infection.23 
1-2-6-3 Adenocarcinoma: 
     This is defined as a malignant neoplasm derived from the 
urothelium showing histologically pure glandular phenotype. 
      Bladder adenocarcinoma is an uncommon malignant tumour 
accounting for less than 2% of all the malignant urinary bladder 
tumours. It includes primary bladder adenocarcinoma and urachal 
carcinoma. It occurs more commonly in males than in females at 
about 2.6:1, and affects adults with the peak incidence in the six 
decade of life.81  
     Macroscopically, the tumour may be exophytic, papillary, 
sessile, ulcerating, or infiltrating and may exhibits a gelatinous 
appearance.23 
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The cytological features of adenocarcinoma, whether primary or 
metastatic, includes acinar groups and papillary clusters of 
vacuolated malignant cells with prominent nucleoli.82 
      Histologically, pure adenocarcinoma of the bladder may show 
different patterns of growth. These include: enteric (colonic) type, 
adenocarcinoma not otherwise specified, signet ring cell, mucinous 
(colloid), clear cell, hepatoid, and mixed. It is not uncommon to find 
a mixture of these growth patterns. There is no generally accepted 
grading system ascribed to adenocarcinoma of the bladder.23 
     The immunohistochemical profile of these tumours that has 
been reported in the literature is variable and closely matches that 
of colonic adenocarcinoma. Reports of cytokeratin (CK) 7 positivity 
are variable ranging from 0-82%, while CK-20 is reported to be 
positive in most bladder adenocarcinomas. Villin has recently been 
reported to be positive in enteric type adenocarcinoma of the 
urinary bladder. Another marker of interest is  B-catenin, which 
has been reported to be of help in distinguishing primary 
adenocarcinoma of the bladder from metastatic colonic 
adenocarcinoma. Secondary involvement is much more common 
than the primary adenocarcinoma of the bladder.23 
     Most cases of adenocarcinoma of the urinary bladder are 
associated with longstanding intestinal metaplasia of the 
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urothelium, such as may be seen in a non-functioning bladder, 
obstruction, chronic irritation, and cystocele. Adenocarcinoma 
arising in exrophy is felt to be secondary to the longstanding 
intestinal metaplasia common to this disease. The risk of 
development of adenocarcinoma in extrophy is in the range of 4.1-
7.1%. Cystitis glandularis is present in invasive adenocarcinoma 
ranging from 14-67% of cases, but its role in the pathogenesis of 
invasive adenocarcinoma is not clear. Adenocarcinoma may also 
arise in conjunction with villous adenoma, S. haematobium 
infection, and endometriosis of the bladder.23 
1-2-6-4 Small cell carcinoma: 
      Small cell carcinoma (SCC) is a malignant neuroendocrine 
neoplasm derived from the urothelium which histologically mimics 
its pulmonary counterpart.23 
      Most if not all, show markers of epithelial differentiation, and 
the majority apparently produce very small amounts of 
polypeptides. Pure  SCC are rare: less than 1 per cent of all 
urothelial neoplasms. Signs and symptoms do not differ from those 
of TCC. Evidence of systemic production of neuroendocrine 
polypeptides is unusual, even though some type of polypeptide 
can be identified in the cells of almost all tumours. Small cell 
carcinomas are often metastatic at the time of clinical detection. 
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The most common locations for disease spread include: regional 
lymph nodes, 56%; bone, 44%; liver, 33%; and lung, 20%.23 
      Choong NW, Quevedo JF, Kaur JS performed a retrospective 
study at Mayo Clinic (Rochester,Minnesota, USA) to characterize 
the clinical and pathologic features of patients with SCC of the 
urinary bladder diagnosed between 1975 and 2003. Forty-four 
patients were identified who had primary bladder small cell 
carcinoma, 61.4% of whom had pure SCC. The male: female ratio 
was 3:1, the mean age was 66.9 years, and the mean follow-up 
was 3.2 years. Twelve patients (27.3%) had stage II disease, 13 
patients (29.6%) had stage III disease, and 19 patients (43.2%) 
had stage IV disease. The overall median survival was 1.7 years.83 
    Almost all the SCCs of the urinary tract arise in the urinary 
bladder. The tumour may appear as a large solid, isolated, 
polypoid, nodular mass with or without ulceration, and may 
extensively infiltrate the bladder wall. 
        Histopathologically, they consist of small, rather uniform cells, 
with nuclear molding, scant cytoplasm and nuclei containing finely 
stippled chromatin and inconspicuous nucleoli. Mitoses are present 
and may be frequent. Necrosis is common. Roughly 50% of cases 
have areas of urothelial carcinoma and exceptionally, squamous 
cell carcinoma and/or adenocarcinoma. This is important, because 
 61
the presence of these differentiated areas does not contradict the 
diagnosis of SCC. 
      The neuronal-specific enolase is expressed in 87% of cases, 
and chromogranin A only in a third of cases. The diagnosis of SCC 
can be made on morphologic grounds, even if neuroendocrine 
differentiation can not be demonstrated. 
     This tumour is charachterized by an aggressive clinical course 
with early vascular and muscle invasion. The overall 5-year 
survival rate for patients with small cell carcinoma of the bladder 
with local disease has been reported as low as 8%.23 
1-2-6-5 Sarcomatoid carcinoma: 
      Sarcomatoid carcinoma (spindle-cell, metaplastic) carcinoma is 
a high-grade neoplasm of the bladder in which a malignant 
epithelial component, clearly identifiable as such (of transitional, 
glandular, squamous, or undifferentiated type) coexists with areas 
having a sarcoma-like appearance. The later may have a non-
specific spidle-cell or pleomorphic look (sometimes admixed with 
osteoclast-like giant cells) or may exhibit specific features of 
mesenchymal differentiation, such as rhabdomyosarcoma, 
chondrosarcoma, osteosarcoma, liposarcoma, or malignant fibrous 
histocytoma. When such specific features are present, the tumour 
may be designated as carcinosarcoma. Whether areas of specific 
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mesenchymal differentiation occur or not, transitions may be seen 
between the two major components, suggesting that the sarcoma-
like areas are also of epithelial nature. Further evidence of the 
epithelial nature of these proliferations is provided by the 
immunoreactivity for keratin often detected in the sarcoma-like 
component.18 
     Another bladder malignancy charachterized by the presence of 
heterologous elements is the rare transitional cell carcinoma 
having areas with morphologic and immunohistochemical features 
of choriocarcinoma and sometimes accompanied by serum 
elevation of HCG.18 
1-2-6-6 None-urothelial tumours: 
    Any mesenchymal lesion can occur in the urinary bladder and a 
great many histologic varieties have been recorded. These 
neoplasms constitute less than 1 per cent of all bladder tumours, 
and their rarity impedes the accumulation of sufficient information 
to permit an adequate understanding of their etiology, 
pathogenesis, and behavior.43 
       In many cases, mesenchymal tumours occupy so much of the 
pelvis at diagnosis that their site of origin cannot be firmly 
established. Although mesenchymal tumours occur in the bladder, 
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there is apparently nothing about their pathology or behavior that is 
peculiar to their origin.43 
1-2-6-7 Malignant mesenchymal tumours: 
     Malignant mesenchymal tumors, although commonly classified 
according to their predominant histologic differentiation, often 
present as bulky pelvic masses composed of primitive 
mesenchymal elements intermixed with cells differentiating toward 
a variety of soft tissue structures. The exact cell type of origin may 
be difficult to determine, and many authorities believe that these 
neoplasms differentiate along multiple lines from multipotential 
stem cells. Prognosis depends more on patient age and the extend 
of the cancer than on histologic subtype; separation into high and 
low grade on the basis of mitoses and nuclear pleomorphism is 
often the pathologist's most important contribution. These tumours 
constitute less than 0.5 per cent of all bladder cancers, and 
descriptions of their characteristics must contain generalizations 
gleaned from isolated case reports and small series with limited 
follow-up.43 
     Most malignant mesenchymal tumours have histologic features 
of muscle differentiation and can be considered myosarcomas. In 
infants and children, these neoplasms usually occur as large pelvic 
masses associated with obstruction of urinary outflow from the 
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ureters and/or urethra. Cases have been reported in association 
with multiple congenital anomalies of the brain as well as 
nephroblastomas. Other cases have occurred in fetuses. The 
disease affects males more often than females in a ratio of 3:1. 
The predominant histologic subtype in children is embryonal 
rhabdomyosarcoma. Grossly, these tumors may arise anywhere in 
the bladder, but they usually involve the base where they appear 
as discrete polypoid masses with glistening, pale gray surfaces. 
When this configuration resembles a bunch of grapes, the term 
botryoid sarcoma has been used. Histologically, edematous 
masses of stellate, round, and spindle tumor cells infiltrate the 
lamina propria and muscular wall and elevate the overlying intact 
urothelium. Cellular density is variable, but cytoplasm is uniformly 
scanty. Cross-striations are distinctly rare. Nuclei are small but 
may vary considerably in shape. Chromatin distribution and 
granularity, as well as the prominence of the nucleoli and mitoses, 
depend on the differentiation of the cells, and these features are 
often variable within any individual tumor. Myosarcomas of the 
bladder in children tend to grow locally rather than to metastasize 
and have high frequencies of recurrence unless widely excised. 
Prognosis varies with the extent of invasion at initial diagnosis and 
adequacy of surgical excision. The eventual outcome is 
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increasingly favorable and several patients have survived more 
than 20 years. 
      Myosarcomas in adult bladders usually present with gross 
hematuria rather than obstruction. Most are located at the bladder 
base in men (sex ratio, 2:1) aged 40 to 60 years. The predominant 
histologic subtype is leiomyosarcoma, and neoplasms tend to be 
more localized, smaller, better differentiated, and more amenable 
to partial cystectomy than their childhood counterparts. Tumours 
are poorly circumscribed and invasive, with ulcerated surfaces. 
Histologiclly, interlacing bundles of spindle cells are a common 
pattern, but various degrees of differentiation may occur. 
Myosarcomas of the adult bladder tend to grow locally but have a 
higher frequency of metastases (usually hematogenous) than do 
childhood myosarcomas in this region. The prognosis in most 
series has been poor. Variations of the common type of adult 
myocarcomas may occur0.43 
     Osteogenic sarcoma of the urinary bladder has been reported 
in patient aged 41 to 83 years (mean, 62 years). The disease has 
occurred almost five times more frequently in men than in women. 
Gross and microscopic criteria for diagnosis do not differ from 
those of osteogenic sarcoma at other sites. Like other sarcomas, 
these tumours tend to grow locally rather than metastasize. In 
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contrast to carcinosarcomas with bone formation, mixed sarcomas 
containing osteogenic areas, and epithelial malignancies with 
osseous metaplasia, pure osteogenic bladder sarcomas have a 
very poor prognosis, with a 1-year survival rate of approximately 
14 per cent.43 
      Malignant fibrous histocytoma (MFH) is one of the most 
frequent soft tissue sarcomas, and in some series, the second 
most frequent sarcoma of the urinary tract in adults.84 It is difficult 
to determine the incidence of urinary bladder malignant fibrous 
histocytoma as it is likely that several tumours previously reported 
as MFH are sarcomatoid urothelial carcinoma. MFH more 
frequently affects men, and is most common in patients in their 5th 
to 8th decade. All subtypes of MFH have been described involving 
the bladder including myxoid, inflammatory, storiform-fasicular, and 
pleomorphic.84 Malignant fibrous histocytoma must be separated 
from the sarcomatoid urothelial carcinoma as well as reactive 
spindle cell proliferations of the bladder. The much more 
commonly encountered sarcomatoid urothelial carcinoma can be 
associated with a malignant epithelial component, and stains 
positively for the immunohistochemical markers of epithelial 
differentiation such as cytokeratin. In contrast, malignant fibrous 
histocytoma   is negative for cytokeratin, and can stain for alpha-1-
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antichymotrypsin, and CD68. Reactive spindle cell proliferations 
lack the cytologic atypia of malignant fibrous histocytoma. 75 
     Isolated case reports of primary bladder sarcomas include 
malignant peripheral nerve sheath tumour, hemangiopericytoma 
after exposure to polyvinyl alcohol, myxoid liposarcoma, malignant 
mesenchymoma, gangilioneuroma, angiosarcoma, and malignant 
varieties of predominantly benign lesions such as granular cell 
tumor. 
1-2-6-8 Haematopoitic and lymphoid tumours: 
      Malignant lymphoma is a malignant lymphoid neoplasm which 
may occur in the urinary blader as a primary or part of a systemic 
disease. It constitutes about 5% of non-urothelial tumours of the 
urinary tract. More than 90% affects the bladder, constituting less 
than 1% of bladder neoplasms. Secondary lymphoma of the 
bladder is common in advanced stage systemic lymphoma, shows 
a slight male predominance and may occur in children. Primary 
lymphoma of the bladder and urethra are rare, affect mainly 
females and occur at median age of 60 years. 
      Among primary urinary tract lymphomas, low grade MALT 
lymphoma is the most frequent in the bladder.85 Reactive germinal 
centers are consistently present while lymphepithelial lesions occur 
in only 20% of cases associated with cystitis cystica or cystitis 
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glandularis. Other bladder lymphomas, like Burkitt lymphoma,T-cell 
lymphoma, Hodgkin lymphoma and plasmacytomas are very rare. 
      Among secondary urinary tract lymphoma, diffuse large B-cell 
lymphoma is the single most frequent histological subtype, 
followed by follicular, small cell, low grade MALT, mantle cell, 
Burkitt and Hodgkin lymphoma. Antecedent or concurrent MALT 
lymphomas in the orbit and stomach, and papillary urothelial 
tumours rarely occur.86 
      Primary MALT of the urinary tract has an excellent prognosis 
after local therapy with virtually no tumour-related 
deaths.Secondary bladder lymphoma as the first sign of 
disseminated disease is termed nonlocalized lymphoma and 
secondary lymphoma in a patient with a history of lymphoma is 
termed recurrent lymphoma. Both secondary lymphomas of the 
bladder have a worse prognosis (median survival 9years and 0.6 
years, respectively), comparable to patients with advanced 
lymphomas of respective histological type elsewhere.23 
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1-2-6-9 Metastatic tumours and secondary extention in 
urinary bladder: 
     These are defined as tumours of the urinary bladder that 
originate from an extravesical, non-urothelial tract neoplasm. The 
most frequent locations of metastases are the bladder neck and 
the trigone.  
        Metastases or, in most cases, direct extension of colonic 
carcinomas to the bladder are the most frequent at 21%, followed 
by carcinomas of the prostate (19%), rectum (12%), and uterine 
cervix (11%). Much less frequent is metastatic spread to the 
urinary bladder of neoplasias of the stomach, skin, breast and lung 
at 2.5-4%. 
     Some metastatic or secondary tumours such as malignant 
lymphoma, leukemias, malignant melanomas, or prostatic 
adenocarcinomas may be diagnosed by routine microscopy. 
However, tumours with less characteristic histological features, 
poorly or undifferentiated high grade tumours require 
immmunhistochemical work-up. 
       Multifocality and prominent vascular involvement in tumours 
with unusual morphology should raise suspicion of metastatic 
tumours.23 
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 1-2-7 Tumour spread and staging: 
        Staging, in addition to grade, is critical in the assessment of 
bladder neoplasms. The staging system most commonly used is 
the **TNM classificationof urinary bladder tumours.23 
     Transurethral resection (TURB) of all visible lesions down to the 
base is required for accurate assessment of depth of tumour 
invasion.2 
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**TNM classification of carcinomas of the urinary bladder 
 
N1   Metastasis in a single lymph node 2cm or less in greatest dimension T - Primary tumour 
TX     Primary tumour cannot be assessed. N2   Metastasis in a single lymph node more than 2 cm but not 
       more than 5 cm in greatest dimension, or multiple lymph  
       nodes, none more than 5 cm in greatest dimension 
T0     No evidence of primary tumour 
N3   Metastasis in a lymph node more than 5 cm in greatest dimension Ta     Non-invasive papillary carcinoma 
 Tis    Carcinoma in situ: "flat tumour" 
M - Distant metastasis T1     Tumour invades subepithelial connective tissue 
MX  Distant metastasis cannot be assessed T2     Tumour invades muscle 
M0   No distant metastasis T2a   Tumour invades superficial muscle (inner half). 
M1   Distant metastasis T2b   Tumour invades deep muscle (outer half) 
 T3     Tumour invades perivesical tissue. 
   Stage grouping T3a   Microscopically. 
M0 N0 Ta Stage 0a T3b   Macroscopically (extravesical mass) 
M0 
M0 
N0 
N0 
Tis 
T1 
Stage 0is 
Stage I 
T4     Tumour invades any of the following: prostate, uterus, 
          vagina, pelvic wall, abdominal wall 
M0 N0 T2a,b Stage II T4a   Tumour invades prostate, uterus or vagina 
M0 N0 T3a,b Stage III T4b   Tumour invades pelvic wall or abdominal wall 
M0 N0 T4a   
M0 N0 T4b Stage IV N -     Regional lymph nodes 
M0 N1,N2,N3 Any T  NX     Regional lymph nodes cannot be assessed 
M1 Any N Any T  N0     No regional lymph node metastasis. 
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1-2-8 Treatment: 
    The treatment for bladder cancer depends on the grade, the 
stage, and whether the lesion is flat or papillary. For small, 
localized papillary tumors that are not high grade, the initial 
diagnostic transurethral resection is all that is done. Patients are 
closely followed with periodic cystoscopies and urine cytology for 
the rest of their life for tumor recurrence.  
When a patient presents with multifocal bladder tumours, 
instillation of topical chemotherapy into the bladder, in the 
immediate postoperative period, can reduce the likelihood of tumor 
recurrence. Several intravesical chemotherapeutic agents are used 
e.g. triethylenethiophosphoramide (thiotepa), an alkylating agent,    
and mitomycin C, an antitumour antibiotic.87, 88   
 After the biopsy site has healed, patient who are at high risk 
of recurrence and/or progression (CIS; papillary tumors that are 
high-grade, multifocal, have a history of rapid recurrence, or are 
associated with lamina propria invasion) receive topical 
immunotherapy consisting of intravesical installation of an 
attenuated strain of Mycobacterium tuberculosis called Bacillus 
Calmette-Guerin (BCG). The therapy presumably works by eliciting 
a local cell-mediated immune reaction that destroys tumor cells. 
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Several immunotherapeutic agents other than BCG have been 
investigated for the prophylaxis of superficial bladder cancer, 
including recombinant IFN-α.89, 90 
Salvage cystectomy, although associated with significant 
morbidity, remains a viable form of therapy for patients in whom 
definitive radiotherapy fails.91 Radical cystectomy is typically 
performed for (1) tumor invading the muscularis propria, (2) CIS or 
high-grade papillary cancer refractory to BCG, and (3) CIS 
extending into the prostatic urethra and extending down the 
prostatic ducts beyond the reach of BCG.  
Advanced bladder cancer is treated by systemic 
chemotherapy. New therapeutic procedures are emerging such as 
photodynamic, laser treatment and gene therapy.92-95 
1-2-9 Prognostic and predictive factors: 
Clinical factors: 
    In general, individual prognosis of infiltrating bladder tumours 
can be poorly predicted based on clinical factors alone. Tumour 
multifocality, tumour size of >3cm, and concurrent carcinoma in 
situ have been identified as risk factors for recurrence and 
progression. Tumour extension beyond the bladder on bimanual 
examination, infiltration of the ureteral orifice, lymph node 
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metastases and presence of systemic dissemination are 
associated with a poor prognosis.  
       Urothelial neooplasms in individuals younger than 20 years 
more commonly occur in males and are predominantly low grade 
with a favorable clinical outcome.96 
      Deletion of the ABH and Lewis blood group antigens appears 
to correlate with an aggressive clinical course, in the form of 
increased probability of recurrence and the acquisition of invasive 
features. 
Morphologic factors: 
      Morphologic diagnostic factors include grade, stage, as well as 
other specific morphologic features. Histologic grade probably has 
prognostic importance for pT1 tumours. As most pT2 and higher 
stage tumours are high grade, its value as an independent 
prognostic marker remains questionable. In long-term programs, 
D. Ramos, et al   demonstrated that PUNLMP have a low 
recurrence rate and a minimal risk for tumour progression in 
comparison with papillary urothelial carcinoma, low grade.97 
      Depth of invasion, which forms the basis of pT categorization, 
is the most important prognostic factor. In efforts to stratify 
category p T 1 tumours further, sub-staging systems have been 
proposed on the basis of the level of invasion into the lamina 
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propria. Tumours that infiltrate beyond the muscularis mucosa 
have a higher progression rate. Carcinoma in situ is more frequent 
with increasing grade and stage of the associated tumour, and 
carcinoma in situ with microinvasion seems to increase the 
propability of aggressive behaviour. Lymphatic and/or vascular 
invasion is associated with decreased survival in pT1 tumours 
(44% 5-year survival). 
     Specific subtypes or histologic variants of urothelial carcinomas 
such as small cell carcinoma, sarcomatoid carcinoma, nested 
variant, micropapillary carcinoma, and lymphoepithelioma-like 
carcinoma may be clinically relavent in patient's prognosis. Margin 
status after cystectomy is also an important predictor of prognosis. 
The pattern of tumour growth has been suggested to be important; 
a pushing front of invasion had a more favourable prognosis than 
tentacular invasion in few studies. 
Genetic factors: 
      Despite marked differences in the prognosis of pT1 and pT2-4 
cancers, these tumours are highly similar on the genetic level. It 
could therefore be expected, that similar genetic alterations might 
be prognostically relevant in all stages. A multitude of molecular 
features has been analyzed for a possible prognostic role in 
invasively growing bladder cancer. Despite all this extensive 
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research, there is currently no molecular parameter that is 
sufficiently validated and has sufficient predictive power to have 
accepted clinical value in these tumours. 
    The nuclear overexpression of p53, as detected 
immunohistochemically and as a likely indicator of a mutation, has 
been found to show a high statistical correlation with disease 
progression in T1 bladder carcinomas. Both grade and stage of 
bladder carcinoma seems to be related to this alteration. 
 Lacombe L, et al in their study concluded that in the group of 
patients with residual disease after BCG therapy, p53 status is a 
better predictor of disease progression than post-BCG stage.98 
     Pfister C, et al studied the prognostic value of Ki-67 index in 
three hundred nineteen patients with newly diagnosed superficial 
(pTa, Pt1) papillary bladder tumours and correlate it with the S-
phase fraction (SPF) measured by flow cytometry. They found that 
the frequency of high Ki-67 expression (> or = 10%) increased with 
stage (P=.005) and grade (P=.001), but not with tumour size or 
multifocality. Tow hundred one patients experienced tumour 
recurrence in a median follow-up of 68 months. Ki-67 index greater 
than 10% was found to be independent predictor of tumour 
recurrence among patients with tumours larger than 3 cm in 
diameter, but not those with smaller size tumours.With regard to 
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the DNA index, they observed a significant but weak correlation 
between Ki-67 expression and the SPF (Spearman's correlaton 
coefficient=0.23, P=.004). In addition, they found that aneuploid 
tumours had significantly higher expression of Ki-67 (2205%) than 
diploid tumours (10.1%) (P=.0006). Moreover, patients with DNA 
aneuploid bladder tumours were more likely to have more than 
10% Ki-67-positive cells than those with diploid tumours. They 
concluded that in patients newly diagnosed superficial (pTa, pT1) 
bladder tumours, a Ki-67 index above 10% is an independent 
predictor of shorter time to recurrence only in those with tumours 
larger than 3 cm.99, 100    
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1-3 OBJECTIVES 
1-3-1 General objectives: 
    To study the pattern of urinary bladder neoplasms among 
Sudanese patients diagnosed at Ibn Sina Hospital, Suba Teaching 
Hospital, and The National Health Laboratory; from January 2004 
through to December 2005 with view to determine epidemiological 
and clinicopathological features of this malignancy. 
1-3-2 Specific objectives: 
1- To determine the histopathological pattern of urinary bladder 
neoplasms among Sudanese patients. 
2- To determine the age, sex, residency distribution, and clinical 
presentation of urinary bladder neoplasms in the studied 
group.  
3- To establish the association of urinary bladder neoplasms 
with tobacco smoking, industrial occupation, use of 
analgesics and medicinal drugs, and schistosomaisis as risk 
factors in Sudanese patients. 
4- To determine the common diagnostic procedures used for 
the diagnosis of urinary bladder neoplasms among 
Sudanese patients. 
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5- To verify different therapeutic options and the outcome of 
urinary bladder neoplasms among the studied group. 
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2- METHODOLOGY 
2-1- Study design: 
        This is a descriptive retrospective study. 
2-2- Study field: 
         The study was carried out at Ibn Sina Hospital, Soba 
University Hospital and the National Health Laboratory at 
Khartoum, Sudan. 
          Ibn Sina Hospital is a specialized hospital for renal and 
gastrointestinal diseases. It receives patients from different regions 
of Sudan for diagnosis and management. 
          Soba University Hospital is a teaching hospital that belongs 
to University of Khartoum. 
          The National Health Laboratory stands as a national 
reference laboratory located at the centre of Khartoum. It receives 
samples from different parts of Sudan. It has several departments 
including histopathology department. It contains the Cancer 
Research Centre of Sudan. 
2-3- Study population: 
        All cases of urinary bladder neoplasms (UBN) presented to 
Ibn Sina, Soba University hospitals or the NHL from January 2004 
through to December 2005. 
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2-4- Inclusion criteria: 
        Patients of (UBN) who were diagnosed histopathologically at 
the three above mentioned centres with or without urine cytology 
and radiological studies. 
2-5- Exclusion criteria: 
      1- Urinary bladder neoplasms patients who had no 
histopathological slides in the histopathology lab of Ibn Sina and 
Soba Hospitals or the NHL were excluded from this study.  
2- Poorly stained slides were excluded from the study. 
3- Any case with no adequate information was also excluded. 
2-6- Materials and methods: 
 Data were collected from the patient's request forms in 
a predesigned questionnaire with detailed history and 
investigations. Cystoscopic findings were collected from 
cystoscopic reporting files in the Cystoscopy Unit in Ibn Sina 
Hospital and from the genitourinary cards (GU cards) in Soba 
Hospital. Patients studied in the year 2005 were interviewed 
directly especially for risk factors while patient's files were referred 
to for those studied in the year 2004. The  histopathological  slides 
of patients included in the study were collected and reviewed by 
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experienced histopathologist to confirm the UBN diagnosis; 
determine the histopathological type of the tumour; and classify the 
UBN using the WHO and the WHO/ISUP grades.  
Microscopic pictures were obtained using Olympus BX 51 
and DP 70 video-microscopy system in the NHL. 
2-7- Statistics: 
The data were electronically analyzed using computer 
S.P.S.S. program, version 10.  
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3- RESULTS 
 
          There were 141 patients with UBN diagnosed at Ibn Sina 
Hospital (ISH), Soba University Hospital, and the NHL during the 
two years of the study. When the slides were reviewed, 35 had no   
available slides or information and so were excluded from this 
study. The remainders (106 cases) were analysed. 
During the two-year study, 101 UBN patients were admitted 
to ISH, 95 patients of them were diagnosed at ISH histopathology 
laboratory (4.5% of the total histopathology samples received 
during 2004 & 2005 in ISH histopathology laboratory), and those 
included in the study were 66 patients. 
Forty-nine patients were admitted to SUH during the two-
years of the study, 32 were diagnosed at SUH histopathology lab 
(1.3% of the total histopathology samples received during 2004 & 
2005 in SUH histopathology laboratory), and 31 of them were 
included in the study. 
In the NHL, 14 UBN cases were diagnosed during the years 
2004 and 2005. They represented 0.9% of the total number of 
 84
cancer cases registered during this period. 9 cases were included 
in the study. 
3-1- Characteristics of the studied patients: 
3-1-1- Age distribution: 
 The ages of the studied patients ranged from 18-90 years 
with a mean of 59.49 ± 13.73. Nine (9%) patients were below 40 
years of age. The youngest patient was 18 years old. The peak 
age of incidence was 60-< 80 years (Figure 1). 
3-1-2- Sex distribution: 
 Eighty-seven (82.1%) patients were males compared to 
nineteen (17.9%) females (Figure 2).Sixty-two of the seventy-two   
TCC cases were males and ten were females, whereas eighteen 
out of the twenty-six SQCC cases were males and eight were 
females. As a result of these findings, the male to female incidence 
rate ratio (R.R) for TCC was 6.2:1 and for SQC was 2.3:1. For all 
UBN it was 4.6:1(Table 1). 
The peak incidence rate for males was at the age of 60-<80, 
while females had two peaks, one at the age group 40-<60, and 
the other at the age group 60-<80 (Figure 3). 
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3-1-3- Geographical distribution of UBN in the studied 
patients: 
 As regard to origin, twenty-six (37.1%) patients were 
originally from the North of Sudan, seventeen (24.3%) from Central 
Sudan, twenty-five (35.7&) from the West, two (2.9%) from the 
East, and no one was from the South of Sudan (Figure 4). 
 Concerning residency, thirty-six (50%) patients were from 
Khartoum, twenty (27.8%) patients from Omdurman, and sixteen 
(22.2%) were from Khartoum Bahri. 
3-1-4 Occupational distribution of UBN in the studied 
patients: 
 Twenty-four (44.4%) patients were found to be labourer, 10 
(41.7%) of them were farmers. Sixteen (29.6%) patients were 
housewives (all females), six (11.1%) employee, three (5.6%) free 
workers, two (3.7%) students, and three (5.6%) patients were of 
other occupations. 
3-1-5- Ethnic distribution of the studied patients: 
 Thirty-three (41.5%) patients were from tribes of the North 
region of Sudan. Among them, Gaaleen tribe has the highest 
incidence of UBN (27.3%). Twenty-six (38.2%) from tribes of the 
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West, five (7.4%) from Central region, four (5.9%) from East tribes, 
and no patient was from the South region of Sudan . 
3-2- Distribution of risk factors in the studied 
patients: 
 Table 2 shows risk factors of UBN in the studied patients. 
Eighteen (43.9%) out of forty-one patients had history of tobacco 
smoking and sixteen (38.1%) out of forty-one patients give positive 
history of urinary shistosomaisis. No history of industrial 
occupation, use of analgesics, or medicinal drugs in the studied 
patients. 
 Fourteen (53.8%) out of 26 TCC cases were smokers, while 
twelve (46.25) were not smokers (P= 0.275). Three (27.3%) out of 
eleven SQCC had positive history of tobacco smoking and eight 
(72.7%) had not (P=0.275) (Figure 5).  
 Eleven (84.6%) out of 13 patients with SQCC had a positive 
history of urinary shistosomaisis, while two (15.4%) had not. Four 
(16%) out of 25 patients with TCC had positive history of urinary 
shistosomaisis and twenty-one (84%) had not (P=0.0001).  
(Figure 6)  
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3-3- Distribution of the clinical presentation of UBN 
among the studied patients: 
 Table 3 demonstrates the various presentations of UBN in 
the studied patients. Gross hematuria was the leading presenting 
symptom (84%). Microscopic hematuria represented only 3.4% of 
the presenting symptoms. About 46.1% of patients with UBN 
presented with other symptoms including suprapubic pain, urine 
retention, and weight loss. 
 The duration of symptoms varied from one week to 6 years. 
Among the total, 52.9% of patients had symptoms <6 months 
duration, while 47.1% had symptoms of >6 months. 
3-4- Distribution of the diagnostic procedure of 
UBN in the studied patients: 
 Fifty-three (75.7%) out of 70 patients were diagnosed first 
radiologically using ultrasonography (U/S), fifteen (21.4%) by 
cystoscopy and biopsy, while only two (2.9%) were diagnosed first 
by IVU. None of the patients in the studied group was diagnosed 
first by urine cytology or CTscan or MRI or surgical resection . 
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3-5-Cystoscopy findings of UBN in the studied 
patients: 
3-5-1- Localization of UBN in the studied patients: 
 In eighty studied cases, the location of UBN was as follows: 
lateral walls, 36 (45%) cases; anterior wall, 5 (6.3%) cases; 
posterior wall, 4 (5%) cases; dome, 3 (3.8%) cases; neck, 2 (2.5%) 
cases; ureteric orifices, 2(2.5%) cases; and multiple sites, 28 
(35%) cases (Table 4).  
3-5-2- Size distribution of UBN in the studied patients: 
Twenty-one (25.6%) out of 82 cases showed tumour size of 
<3cm at presentation, thirteen (15.9%) were 3-6cm, and forty-eight 
(58.5%) were of >6cm at presentation. Figure 7 shows the 
relationship between size and grade (WHO/ISUP) of UBN in the 
studied patients. 
3-6-Type of specimens in the studied patients: 
Eighty-two (77.4%) of the specimens were TUBPs, eighteen 
(17%) TURBTs, four (3.8%) cystectomies, one (0.9%) is true-cut 
needle biopsy, and one (0.9%) specimen is obtained during 
laprotomy (Table 5). 
 
 89
3-7- Histopathological characteristics of UBN in 
the studied patients: 
3-7-1- Histopathological patterns (diagnosis): 
  Figure 8 shows the different histopathological patterns of 
UBN in the studied patients. TCC with its different grades is seen 
in seventy-two (67.9%) cases (Figures 9-12). Various variants 
were identified (Figures 13-15). Twenty-six (24.5%) were SQCCs 
(Figures 16-18), three (2.8%) were TCC with sqamous 
differentiation (Figure 19), and five (4.7%) others. The other 
patterns include two adenocarcinoma (Figure 20), liposarcoma 
(Figure 21), leiomyosarcoma, and malignant fibrous histocytoma 
(Figure 22). 
3-7-2- Configuration of TCC cases in the studied 
patients: 
 Thirty-nine (51.3%) out of 76 TCC cases were papillary, 
nineteen (25%) solid, and eighteen (23.7%) showed both papillary 
and solid configuration. 
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3-7-3- Muscle invasion of TCC cases in the studied 
patients: 
 There were twenty-eight (36.8%) of the 76 TCC cases with 
muscle invasion at diagnosis and twenty-one (27.6%) with no 
muscle invasion, whereas twenty-seven (35.5%) cases contain no 
muscle to assess invasion in the specimen provided.Figure 23 
shows the relationship between muscle invasion and outcome of 
UBN in the studied patients. 
3-7-4- WHO grading of TCC cases in the studied 
patients: 
 Forty-four percent of the TCC cases presented at grade III, 
30.7% at grade II, 22.7% at grade I, and 2.7% (two cases) graded 
as papillomas using the WHO (1973) grading system (Table 6). 
3-7-5- WHO/ISUP grading of the TCC cases in the 
studied patients: 
 There were 43.4% of TCC cases graded as papillary 
carcinoma of high grade, 52.6% papillary carcinoma of low grade, 
1.3% papillary neoplasm of low malignant potential, 1.3% pailloma, 
and 1.3% (one case) was graded as flat neoplasm using the 
WHO/ISUP grading system (Table 7). 
 91
3-7-6- Differentiation of SQCC cases in the studied 
patients: 
 In the current study, twelve (42.9%) were poorly 
differentiated SQCCs, nine (32.1%) moderately differentiated, and 
seven (25%) cases were well differentiated SQCCs. 
3-7-7- Keratinisation of SQCCs in the studied patients: 
 Nineteen (67.9%) of the 28 SQCCs were non-keratinized, 
and nine (32.1%) were keratinized SQCCs. 
3-8- Distribution of treatment   used in the 
studied patients: 
Twenty-seven (25.5%) of all cases were treated by TURBT 
alone, 10 (9.4%) TURBT with radiotherapy, 6 (5.7%) TURBT with 
BCG, 6 (5.7%) received radiotherapy alone, 3 (2.7%) underwent 
salvage cystectomy with diversion of urine, 2 (1.9%) salvage 
cystectomy alone, one (0.9%) bypass with radiotherapy, one 
(0.9%) cystectomy with radiotherapy, one (0.9%) debulking with 
cyto-dithermy, one (0.9%) urine diversion alone, one  (0.9%) 
radical cystectomy, and two (1.9%) did not receive any treatment 
(Table 8). 
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3-9- Outcome of UBN in the studied patients: 
Fifteen (46.9%) patients (out of 32 patients followed through 
the two years of the study) passed because of UBN, twelve 
(35.5%) were alive and well, four (12.5%) were alive with 
recurrences, and one (3.1%) was alive and ill (Table 9). Figure 24 
shows the relationship between grades and outcome of UBN 
among the studied patients. 
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Figure (1): Age distribution in UBN in the studied 
patients ( N = 106 )
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Figure (2): Sex distribution in UBN in the 
studied patients ( N = 106)
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Figure (3): Age specific incidance rate of UBN in males and females among 
the studied patients (N=106)
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Figure (7): Relationship between size and grade (WHO/ISUP) 
of UBN in the studied patients (P=0.761) 
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Figure (9): Non-invasive urothelial neoplasm, urothelial 
papilloma. Discrete papillary fronts, with occasional 
branching but, without fusion. (H/E. X20) 
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Figure (10): Non-invasive papillary urothelial carcinoma, low 
grade. Note variation in nuclear polarity, size, shape and 
chromatin pattern (H&E. X20). 
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Figure (11): Papillary urothelial carcinoma, low grade with 
lymphoplasmacytic infiltration in the core (H&E. X20). 
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Figure (12): Papillary urothelial carcinoma, high grade. The 
architecture is disordered and there is marked nuclear 
pleomorphism, hyperchromasia and necrosis. Mitotic figures 
are readily visible (H&E. X40). 
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Figure (13): Infiltrative urothelial carcinoma clear cell variant. 
A clear cell pattern with glycogen-rich cytoplasm is 
noted  
(H&E. X40). 
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Figure (14): Infiltrative urothelial carcinoma, nested variant  
(H&E. X40). 
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Figure (15): Infiltrative urothelial carcinoma, undifferentiated 
variant (H&E.X40). 
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Figure (16): Squamous cell carcinoma with Shistosoma 
heamatobium eggs (PAS.X40). 
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Figure (17): Squamous cell carcinoma of the urinary bladder 
well differentiated with keratinization (H&E. X40). 
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Figure (18): Squamous cell carcinoma, poorly differentiated 
(H&E. X40). 
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Figure (19): Infiltrative urothelial carcinoma, with squamous 
differentiation (H&E. X40). 
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Figure (20): Adenocarcinoma of the urinary bladder. Multiple 
glands embedded in a loose stroma (H&E. X20). 
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Figure (21): Urinary bladder liposarcoma (H&E.X20) 
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Figure (22): Urinary bladder malignant fibrous histocytoma 
(H&E. X40) 
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Table (1): Sex distribution and male to female incidence rate 
ratios for TCC and SQCC among the studies patients 
 
Female Male Incidence 
Rate 
Ratio Percent FrequencyPercentFrequency 
 
6.2:1 13.9% 10 86.1% 62 TCC 
2.3:1 30.8% 8 69.2% 18 SQCC 
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Table (2): Distribution of risk factors of UBN in the studied 
patients 
 
 
Valid 
No 
Valid 
percent No
Valid 
percent YesRisk factor 
41 56.1% 2343.9% 18 Tobacco smoking 
36 100% 360.0% 0 Industrial occupation 
36 100% 360.0% 0 Use of analgesics 
36 100% 360.0% 0 Use of medical drugs 
42 61.9% 2638.1% 16 History of urinary schistosomiasis 
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Table (3): Presenting symptoms of UBN among the studied 
patients 
 
 
Percent Frequency Symptoms 
84.3% 75 Gross haematuria 
3.4% 3 Microscopic haematuria 
39.3% 35 Painful micturition 
15.7% 14 Urgency and frequency 
3.4% 3 Palpable pelvic mass 
46.1% 41 Others 
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Table (4): Localization of UBN in the studied patients 
 
 
Percent Frequency Site 
45% 36 Lateral walls 
6.3% 5 Anterior wall 
5.0% 4 Posterior wall 
3.8% 3 Dome 
2.5% 2 Neck 
2.5% 2 Ureteric orifices 
35.0% 28 Multiple 
100% 80 Total 
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Table (5): Type of specimens of the studied patients 
 
 
Percent Frequency Type of specimen 
77.4% 82 TUBP 
17.0% 18 TURBT 
3.8% 4 Cystectomy 
0.9% 1 True-cut needle biopsy 
0.9% 1 Laprotomy 
100% 106 Total 
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Table (6): WHO grading of TCC cases in the studied patients 
 
 
Percent Frequency Tumour grade 
2.6% 2 Papilloma 
22.4% 17 Grade I 
31.6% 24 Grade II 
43.4% 33 Grade III 
100% 76 Total 
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Table (7): WHO/ISUP grading of TCC cases in the studied 
patients 
 
 
PercentFrequency Tumour grade 
1.3% 1 Papilloma 
1.3% 1 Neoplasm of low malignant potential 
52.6% 40 Low grade papillary carcinoma 
43.4% 33 High grade papillary carcinoma 
1.3% 1 Flat 
100% 76 Total 
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Table (8): Distribution of treatment used in the studied 
patients 
 
 
PercentFrequency Treatment 
25.5% 27 TURBT 
9.4% 10 TURBT+ Radiotherapy 
5.7% 6 TURBT+ BCG 
5.7% 6 Radiotherapy 
2.7% 3 Salvage cystectomy+ diversion of urine 
1.9% 2 Salvage cystectomy 
0.9% 1 Bypass+ Radiotherapy 
0.9% 1 S. cystectomy+ Radio 
0.9% 1 Debulking+ cystodithermy 
0.9% 1 Radical cystectomy 
0.9% 1 Urine diversion 
1.9% 2 None 
100% 106 Total 
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Table (9): Outcome of UBN in the studied patients 
 
 
Percent Frequency Outcome 
46.9% 15 Passed 
37.5% 12 Alive and well 
12.5% 4 Alive with recurrences 
3.1% 1 Alive and ill 
100% 32 Total 
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4-1- DISCUSSION 
 
        This is a descriptive retrospective study about UBN in 
Sudanese patients. It was carried out in the period from January 
2004 to December 2005 and includes analysis of 106 cases. It was 
conducted in two main urological centres as well as the National 
Health Laboratory. 
       Urinary bladder neoplasms are a heterogeneous group of 
tumours with different subtypes and different behavioural 
processes.  This had led   various authors to study different and 
specific entities within the same topic, the thing that makes 
comparison difficult. Few similar epidemiological and 
clinicopathological studies were done. Instead there is a lot of work 
in the diagnostic markers, especially cytogenetically, worldwide. In 
Sudan, one remote similar study was conducted in the period of 
January 1984 to December 1988.30  
The last available data shows that bladder cancer represents 
4.3% of all cancer cases registered at the Cancer Research 
Centre, NHL (The seventh common malignancy in men in 
Sudan).101 An epidemiological search on UBN revealed a relatively 
low incidence of UBN in Sudan, compared to developed countries. 
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Using the Age Standardized Rate (ASR) which is expressed per 
100.000 populations, it is 4.7 in Sudan, while 24.5 in USA and 17.0 
in UK.1 It is also lower than incidence in Egypt (37.1) and Iraq 
(17.7), both countries are known for their high prevalence of 
urinary schistosomiasis. ASR in Sudan is higher than it is in 
Kenya.1  
In this study, bladder cancer accounts for 0.9% of the total 
number of cancer cases registered during the period of the study. 
It is not the exact incidence because many other cases were 
diagnosed in special laboratories, other hospitals, or clinics and 
were not registered. The real number of UBN is far greater than 
that registered in the NHL. In Sudan as in most developing 
countries, there is at present no reliable statistical information on 
absolute cancer rates. 
According to the available data during the later years in 
Sudan, there has been a significant increase not only in the total 
number of cancers but also in the cancers of urinary bladder. 
Salwa Sir El khatim reported one hundred and ninety six patients 
seen at four urological centres as well as the Radiation and 
Isotope Centre, Khartoum, in the period January 1984 to 
December 1988, while this study reported 141 cases reviewed in 
three centres in two years interval. The socioeconomic changes 
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and urbanization, which had taken place in Sudanese society, 
entails characterization of this cancer, which is usually linked with 
economic development. 
In this series, the commonest age group ( 60- <80 ) is similar 
to that reported by Waihenya CG and Mungai PN, but different in      
Salwa's study  , where it was 50 – 70 years.29,30 The median age of 
patients was 61 years which is higher than that  of Zulfo's studied 
patients ( 51.1 years ).102 The mean age of this study is 59.5 years 
which is close to that reported from United States ( 57.8 years ) but 
lower than that reported from Greece ( 66.7 years ).103, 65 
In this study, our results are in accordance with the literature 
regarding the occurrence of high number of cases among males. 
The male to female ratio (4.6:1) is similar to   Salwa's   study and 
also to a study carried in Kenyatta National Hospital, Nairobi, 
Kenya (4:1) and Saudi Arabia (4.4:1).30,29,26 It differs from that done 
by Nazar Zulfo about superficial transitional bladder cancer where 
the male to female ratio was 1:1.102 It is   higher than ratios 
reported from United States (2.4:1) and Greece (3.9: 1).103, 65 
Geographically, most of the patients (37.1 %) were originally 
from the North region of Sudan. Central Sudan achieved the third 
percent (24.3%).This is not similar to Salwa's study where most of 
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her patients were  originally from central region which is the area 
most heavily affected with schistosomiasis in Sudan. 
The explanation to the lower incidence of UBN in the central 
region in our study inspite of the high infestation rate with urinary 
schistosomiasis could lie either in the fact that people in endemic 
areas receive anti-bilharzial treatment frequently at an earlier age 
or that many patients with squamous cell carcinoma in the bladder 
die before having any medical advice. A third possibility is that 
urinary schistosomiasis run a more benign course and its natural 
history become different.104 
 The West region of Sudan showed the 2nd high incidence 
(35.7%), while no one was found to be from the South. These 
discrepancies may not be due to real geographical variation but 
rather to the surgical, histopathological, and treatment services 
available in the Capital. Poor financial status, difficult 
transportation, war situations, and lack of awareness may be 
among the major reasons why patients do not report from 
Southern and Eastern Sudan. 
Tribes of the North dominated, as most of the studied 
patients were from the North region. Galeen tribe showed the 
highest incidence. This is probably due to their easy transportation 
to Khartoum. 
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In this study, most of the patients were labourer (44.4%). 
41.7% of them were farmers. These results were similar to those 
reported from Kenya and Egypt.29, 105 It has been suggested that 
this could be attributed to the fact that squamous cell carcinoma of 
the bladder which is common in areas endemic with urinary 
schistosomiasis occurs mostly in farmers by the virtue of being 
subjected more to infestation by schistosomiasis. In Egypt it is well 
known that this sector of the community is the main victims of 
schistosomiasis and its complications including cancer. This 
makes the male to female ratios higher in areas endemic with 
schistomiasis such as Egypt (9:1) compared with non-
schistomsomal countries such as United States (2.4:1) and Greece 
(3.9:1).103, 65 
In the present series, the interpretation of risk factors of UBN 
was a bit strange. Although tobacco smoking is a well established 
risk factor of UBN in the literature, this study showed no significant 
relationship between tobacco smoking and development of UBN 
among the studied Sudanese patients (P= 0.275). This could be 
explained by the low number of patients that were interviewed 
directly for tobacco smoking in the study 41 ( 38.7% ) and some of 
them may omit the truth or did not mention that they smoke once 
upon their lives even they were not smokers during the study 
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period. Limited background history and poor clerking in the 
patient's files might also be implicated. 
In the current study, there was no single case that showed a 
positive history of either occupational exposure or chronic use of 
analgesics containing phenacetin or medicinal drugs. Sudan is not 
an industrial country, this might lie behind the finding that 
occupational exposure is not considered to be a risk of UBN 
among Sudanese patients. They also  use paracatamol and aspirin 
as analgesics, and do not use phenacetin compounds.  
Patients who use medicinal drugs such as 
cyclophosphamide in Sudan usually die because of original 
disease rather than developing UBN. 
Arsenic-contaminated water was not studied as a risk factor 
of UBN among Sudanese patients in this study because it needs a 
biochemical analysis of water. It is suggested to be behind the high 
incidence of UBN in areas not endemic with schistosomiasis. 
Arsenic is used in pesticides and North Sudan which is an 
agricultural area showed a high incidence of UBN in the present 
study. It remains to be studied. 
In the present series 38.1% of patients gave a past history of 
urinary schistosomiasis. 84.6% of the patients with SQCC had a 
past history of urinary schistosomiasis. This study yielded a highly 
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significant relationship between urinary schistosomiasis and 
development of SQCC (P=0.0001).  
 In Salwa's study 31% of patients gave a past history of 
urinary schistosomiasis, while in Iraq 50% had a positive history of 
urinary schistosomiasis.30, 106 
The commonest presenting symptom was haematuria 
occurring in 87.7% of our patients. This was described as gross 
and painless haematuria in   84.3% of cases. Haematuria is by far 
the commonest and can be the only presentation of urinary 
schistosomiasis. Patients who develop bladder neoplasm on top of 
schistosomaisis do not appreciate development of newer 
symptoms and they attribute haematuria to schistosomiasis and 
accordingly most of them present with advanced disease. This in 
part explains the large number of patients presenting with other 
symptoms (46.1 %) including suprapupic mass, obstructive 
uropathy and weight loss on the first visit.  
These results were similar to those of Salwa Sir El khatim 
(82% of patients presented with total painless haematuria) as well 
as  Zulpho (84.6% of patients presented with haematuria).30, 102 
The exact time lapse between the beginning of the 
symptoms and the diagnosis of UBN is variable. In this study, it 
varies from one week to six years. 
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In this study, the percentage of cases of UBN diagnosed first 
by ultrasonography was high (75.7%), compared to 21.4% by 
cystoscopy and biopsy. Ultrasonography is a non-invasive 
radiological procedure which is easy and available, this is why it is 
requested first. It gives the suggestion of UBN, but the definite 
diagnosis is by cystoscpy and biopsy. 
IVU, which needs dye contrast, although useful its role in 
diagnosing UBN is declining. It diagnosed only 2.9% of patients in 
this study. None of the patients in the study was diagnosed by 
CTscan, MRI or urinary cytology. CT scan and MRI are costy 
procedures and not yet commonly available in Sudan. They were 
requested later in the disease and are useful primarily for 
evaluating the upper urinary track and in staging the more 
advanced lesion.  
Urine cytology is of little practical value in the initial 
evaluation of most bladder tumours because of their accessibility 
to formal biopsy. The greatest value of urinary bladder cytology is 
in the follow up evaluation of patients who have received surgical 
or radiotheraputic treatment for bladder neoplasm. 
 Cystoscopically, the lateral walls were found to be the 
commonest site of occurrence of UBN in our series (45%). This is 
nearly similar to what was reported from UK where the lateral walls 
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were affected in 37% of cases.I6 It differs from Salwa's study where 
the bladder base was found to be the commonest site of 
occurrence of cancer (28%).8 It also differs from what was reported 
from Egypt where the base was affected in 44.6% of cases.107  
       Although most of our cases presented with large tumour size 
(>6 cm) (58.5%), tumour size did not show significant relationship 
to outcome (P=0.761).  
       Since cystoscopy and biopsy is the mainstay of diagnosis, 
most of the specimens in this study were transurethral bladder 
biopsies (77.4%). 
 The feature that the disease in our patients have in common 
with non-bilharzial bladder neoplasms is that histologically the 
majority (67.9%) were transitional cell carcinomas, while sqamous 
cell carcinoma accounts for 24.5% of the cases which is high 
compared to a frequency of less than 5% in UK and USA.23 Yet, 
very low compared to the figures from Egypt where sqamous cell 
carcinoma forms the bulk of cases (66.7%), and transitional cell 
carcinoma forms only 23.4%, and from Iraq where sqamous cell 
carcinoma forms 65% and transitional cell carcinoma forms only 
28% of cases.107,106  
         Surprisingly, in USA - a non-bilharzial country- there are 
differences in histology by race, with Whites having 95% urothelial 
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and 1.3% SQCC, while the proportions are 87.8% and 3.2%, 
respectively, in Blacks.23 In South Africa, there are marked 
differences in histology between Blacks (36% SQCC, 41% 
urothelial) and Whites (2% SQCC, 94% urothelial).23 The 
association between race and the prevalence of SQCC remains to 
be answered. 
      The evidence by the authors already cited in favour of an 
association between urinary shistosomaisis and bladder neoplasm 
has been advanced on epidemiological, clinical and morphological 
grounds.23 They point to the finding that bladder neoplasm is much 
more frequent in areas where shistosomaisis is prevalent than in 
regions where it is not known or is of minor importance. However, 
challenging the arguments to the contrary has been produced by 
other workers. For instance, it is mentioned that vesical cancer is 
not as common in some African countries despite shistosomal 
endemicity. Furthermore, in Uganda, squamous cell carcinoma is 
the commonest histological type of bladder cancer in the presence 
of little or no shistosomal infection. Doge (1962) found only one 
case of vesical shistosomaisis in 81 bladder cancers and Anthony 
(1967) found none in 127 cases. These arguments have focused 
attention on other operating factors. In Uganda for example, it has 
been suggested that urinary obstruction consequent on urethral 
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stricture from gonococcal infection might be incriminated.108 As 
regards to the statistical relationship of bladder cancer to 
shistosomal endemicity, it has been argued that the host-parasite 
relationship might differ from one place to another, that various 
strains might differ in their genetic experience and susceptibility, 
and that not merely the presence but also the severity of 
infestation has to be taken into consideration.109-111  
 Different variants of TCC were identified in this study 
including the nested variant which is rare and a low grade TCC 
with lymphoplasmacytic infiltrate in the fibrovascular core which is 
unique (not found in the literature).  
         In our patients, 51.3% of the TCC neoplasms were of 
papillary configuration, 25% were solid, and 23.7% were both 
papillary and solid. This is in contrary to the findings of Salwa Sir El 
Khatim where 58% of tumours were solid, and only 33% were 
papillary. It is also not in agreement with reports from Egypt and 
Iraq where solid fungating tumours constitute 68.5% and 52% of all 
bladder neoplasms respectively. It should be noted that the solid 
tumours form only 18.9% of non-bilharzial bladder cancer, 81.1% 
of them being papillary.112  
       The classification and grading of non-invasive, intraepithelial 
neoplasms of the urothelium are based on the morphological 
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pattern of growth- that is, papillary or flat- and on their degree of 
architectural and cytological abnormalities. Recent advances in the 
morphological, molecular, and quantitative evaluation of these 
lesions have contributed to the refinement of the current 
classification and grading schemes. However, some controversies 
on the precise criteria and terminology, especially when the 
papillary lesions are concerned, are still present.113  
Changes in classification have their own inherent problems, 
tending to lead to confusion, at least for a period of time. From 
practical point of view, in this study we used both the WHO and the 
latest WHO/ISUP classification.  
The key points of the latest WHO/ISUP classification of non-
invasive urothelial tumours are: the description of the categories 
has been expanded in the current version to improve their 
recognition; one group (papillary urothelial neoplasm of low 
malignant potential) with particularly good prognosis does not carry 
the label of ''cancer''; it avoids use of ambiguous grading such as 
grade 1/2 or 2/3 (according to the WHO classification published in 
1973); the group of non-invasive high grade carcinomas large 
enough to contain virtually all those tumours that have biological 
properties (and a high genetic instability)  similar to those seen in 
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invasive urothelial carcinoma. This scheme is meant to replace the 
1973 WHO classification.114 
 Samaratunga et al investigated the risk of progression for the 
WHO/ISUP 1998 and WHO 1973 classifications. They observed 
progression in 8% of patients with PUNLMP and 11% of patients 
with grade I papillary carcinoma (WHO classification). The same 
group claim an advantage of the WHO/ISUP system over the WHO 
system in that the WHO/ISUP classification recognised a larger 
proportion of cancers with a poor prognosis.115 
Nevertheless Oosterhuis et al found that the prognostic value 
of the   WHO/ISUP classification is limited, thus questioning the 
clinical role of this new system in comparison with conventional 
grading systems .116 
According to Bostwick and Mikuz, the WHO 1973 classification 
and grading of bladder tumours is recommended with minor 
modifications for international use to allow valid comparison of 
results between different clinical centers.117  
Seitz M, et al presented the new 2004 WHO/ISUP classification 
of urinary    bladder tumours emphasizing the changes in relation 
to the former classifications focusing on histological typing, grading 
and molecular   characterization. They recommended that until the 
new classification is finally validated and those working in the field 
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have become familiar with it, the WHO classification of 1973 
should be mentioned additionally in the histopathology report.118 
      In our study we found closely similar findings of both 
classification schemes concerning grade III (WHO classification) 
and papillary urothelial neoplasms, high grade (WHO/ISUP 
classification) with a percentage of 44 and 43.4 respectively. The 
explanation of this high percent of high grade tumours at diagnosis 
might be the late presentation of our patients.  
       The high percent of papillary urothelial neoplasms, low grade 
in this study was attributed to that we considered both grade I and 
grade II (WHO classification ) as papillary urothelial neoplasms, 
low grade in the WHO/ISUP classification to avoid ambiguous 
grading. This was a pitfall, because the term ''PUNLMP'' was 
introduced to replace WHO grade I carcinoma in recognition of the 
low probability of recurrence or progression of this neoplasm, 
especially after complete removal, and the preference not to label 
these patients with the term ''cancer''. 
In the current study, concerning the histological type SQCC, 
most of the cases were poorly differentiated (42.9%) and none 
keratinized (67, 9%). This could be explained partially by the late 
presentation of our patients and to some extent by the aggressive 
nature of the SQCC.   
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Twenty five percent of our patients who had non-invasive 
tumours at presentation were treated by TURBT alone. In 9.4 % of 
the resected specimens at histology showed invasion of the 
superficial muscles and those had supplementary radiotherapy.  
The percent of patients who had TURBT + BCG or received 
radiotherapy alone (each 5.7%) exceeds that of patients 
underwent salvage cystectomy   and diversion of urine (2.7%).  
The aim of urinary bladder cancer treatment with intravesical 
chemotherapy is three fold: to eradicate existing diseases, prevent 
recurrence    and prevent tumour progression.119 Comparing 
resection with and without adjuvant intravesical chemotherapy, an 
approximately 15 % short – term decrease in tumour recurrences 
with chemotherapy is obtained, although no effect on progression 
was proven.120  
The importance of early administration has been highlighted 
by the positive results of a single, early instillation of 
chemotherapy, with a reported mean reduction in recurrence rate 
of 12-27%. Immunotherapy in the form of bacillus Chalmette-
Guerin has generally proven more efficious   than 
chemotherapy.120  
T1 transitional cell neoplasm of the urinary bladder is 
associated with a significant risk of tumour progression when 
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transurethral resection (TURBT) is the only treatment. Additional 
intravesical immunotherapy can reduce this risk; however, long-
term results of more than 5 years of follow up indicate that almost 
half of the patients may loose their bladder or even die due to 
recurrent tumour.  
The alternative to TURBT is cystectomy at either the initial 
presentation or time of first recurrence. However, although the 
results of this treatment strategy are encouraging, an unknown 
percentage of patients will loose their bladder and go on to 
experience all possible complications of urinary diversion 
unnecessarily. The central issue of conservative treatment but also 
the indication for cystectomy is the quality of TURBT.121 Moreover, 
even in cases of a so-called 'correct TURBT', a significant 
percentage of residual tumour is left behind and will be the source 
of local recurrence or progression.121 
Janson S, et al studied residual tumours at a second-look 
resection in patients resected 4-8 weeks earlier for T1 tumours of 
the urinary bladder. They concluded that the majority of residual 
tumours detected at this stage are potentially dangerous; 
therefore, early second-look resection followed by intravesical 
installation therapy is mandatory in patients with T1 tumours of the 
urinary bladder.122 
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In this study, only thirty two patients were followed during the 
two years of the study. Of them, 46.9% passed. The commonest 
cause of death in our patients was renal failure due to involvement 
of the ureters rather than wide-spread metastasis. 
Inspite of the short duration of the study,   follow up was a 
real problem. This is related to many factors, the most important of 
which is that most patients came from rural areas where means of 
transportation and communication to the urological centres in 
Khartoum are difficult and costy, especially in the raining season 
when this can be impossible. The second reason is that very few 
rural hospitals are equipped with cystoscopic armamentarium and 
nearly all the few urological surgeons are based in Khartoum. A 
third reason which made follow up difficult in those patients is that 
our patients do not appreciate coming for routine follow up or 
check-cystoscopy once they are symptom-free especially , 
haematuria-free . 
The recurrence rate within five years after partial resection 
was reported as high as 78%.123 However, in our series only 
12.5% of resected group show recurrences and this low 
percentage is mostly attributed to the difficulties in follow up of 
patients. 
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This study proved a statistically significant relationship 
between muscle invasion in TCC and the outcome of the disease 
(P=0.002). This is similar to the results of Blaveri E, et al who 
evaluated the associations between measures of genomic 
instability and bladder cancer clinical phenotype using array-based 
comparative genomic hybridization. They found that the fraction of 
genome altered (FGA) was associated with worse outcome in 
muscle-invasive tumours, independent of other clinicopathologic 
parameters (P=0.002).124 
In this study, tumour grade showed a significant association 
with the outcome (P=0.006). This is closely related to the findings 
of Messing EM, et al, that of the high-grade or invasive cases, the 
proportion of late stage (T2 or higher) tumours was significantly 
lower in the screening-detected bladder cancers compared to 
unscreened ones (P-0.007). They drew attention to the importance 
of haematuria home screening which detects high-grade cancers 
before they become muscle invading and significantly reduces 
bladder cancer mortality.125 However, testing for microhaematuria 
does not meet the requirements of a modern screening and 
diagnostic test. Better alternatives are presently available, and in 
the near future we will likely see urine tests for specific clinical 
conditions.126 Current studies do not support the routine screening 
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for bladder cancer. However, prospective long-term studies are 
required to evaluate the benefits of bladder cancer screening, 
particularly in those at high risk.127 It is time to detect high-grade 
cancers early, in a high risk population, cytogenetically in order to 
reduce bladder cancer mortality. 
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4-2- CONCLUSION 
When all the findings in our series are considered together, it 
can be said that pattern of urinary bladder neoplasms in Sudan 
tend to share some common features with bilharzial bladder 
cancer in other countries on one hand, and with non-bilharzial 
bladder neoplasms on the other. 
Possibly more cases of bladder neoplasms are emerging in 
the recent years either because the level of awareness among the 
patients is increasing or the methods of early detection of tumours 
are improving as improvements in cysoscopies and other 
investigation tools. 
 Despite limitation in the background history, detailed 
histological diagnosis and staging, this study showed a significant 
relationship between urinary schistosomal infestation and 
development of squamous cell carcinoma of the urinary bladder. 
 A significant correlation was identified in this study between 
tumour grade as well as muscle invasion and the outcome of 
urinary bladder neoplasms. 
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4-3- RECOMMENDATIONS 
A more accurate assessment awaits detailed prospective 
studies comparing regions within Sudan itself where 
schistosomiasis is endemic with others where it is not known to 
occur.  
More searches are needed to be carried to address the 
possible environmental and community related risk factors such as 
arsenic and others, especially in Northern and Western Sudan. 
We feel that a close follow up of patients with chronic urinary 
schistosomiasis by regular cystoscopies, possibly cytology and 
histology of bladder tissue for metaplasia, urine markers, and even 
cytogenetically can be of some help for early detection of this 
aggressive neoplasm. 
The community medicine and public health services has a 
big role to play in teaching people in the endemic areas, and 
measures should be taken to detect complications at   an early 
stage and this can be achieved only at a primary medical care 
level. 
Detailed histopathological diagnosis, grading and staging, 
and improvement of cancer reporting and registering are highly 
recommended. 
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 ﻢﻴﺣﺮﻟا ﻦﻤﺣﺮﻟا ﷲا ﻢﺴﺑ 
University of Khartoum 
Faculty of Medicine 
Postgraduate Medical Studies Board 
Questionnaire 
Bladder Cancer   
Date:    /   /                                           Serial No.: 
Hospital:  1-Ibn Sina            2-Suba                 3-NHL (Khartoum) 
• Lab. No.: ………….        Consultant in charge: ………………. 
File No. …………………… 
1- Name: ………………………………..            Address: …………. 
2- Age (in years): ……………………………. 
3- Gender:           a- Male                b- Female 
4- Tribe: ………………………………………5-Occupation: 
………………. 
6- Residence: …………………………………7-Origin: 
……………………. 
8- Risk factors:  History of: 
a- Tobacco smoking.      Yes  No             Not 
known: 
b- Industrial occupation. Yes   No              Not 
known:       
c- Analgesics.                 Yes  No              Not 
known:      
d- Medicinal drugs.         Yes  No              Not 
known:      
e- U. Schistosomiasis.    Yes  No              Not 
known:      
 
9- Clinical remarks: 
a- Haematuria :    i- Gross . 
         ii- Microscopic . 
b- Painful micturition. 
c- Urgency and frequency. 
d- Palpable pelvic mass. 
e- Others:………………………. 
10- Diagnosed by: 
a- Cystoscopy and biopsy . 
b- Imaging :        i- IVU                    ii- U/S 
       iii- CTscan             iv- MRI 
c- Surgical resection. 
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                    d- Urine cytology. 
        11- Cystoscopy findings: ………………………................ 
9- Histopathology:  
     Type of specimen:  TUBP            TURBT       Cystectomy 
  Gross: …………………………….. 
              Microscopy:………………………. 
              Diagnosis:………………………… 
              Grading:…………………………... 
 
 
 
 
 
